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ABBREVIATIONS 
 
 
AFLP amplified fragment-length polymorphism 
BL Beijing lineage 
bp base pair 
BRAC Bangladesh Rural Advancement Committee 
CCS critical community size 
CD cluster of differentiation 
CDC Centre for Disease Control (US Government, Atlanta) 
CHW community health worker 
COPD chronic obstructive pulmonary disease 
DA Destiny Associates 
DNA deoxyribonucleic acid 
DOTS directly observed treatment short-course 
DR direct repeat 
EEA1 early-endosomal autoantigen 1  
EMB or E ethambutol  
FLiP fast ligation-mediated PCR 
GoB Government of Bangladesh 
HCW health care worker  
HIV human immunodeficiency virus 
ICCDR,B Centre for Health and Population Research, Bangladesh  
IL inter leukin 
INF Interferon 
INH or I Isoniazide 
IS inter section 
IUATLD International Union Against TB and Lung Disease 
KP Koch’s phenomenon 
LAM Lipoarabinomannam 
M. tuberculosis Mycobacterium tuberculosis 
ManLAM mannosylated lipoarabinomannam 
mce mycobacterium cell entry operon 
MCH major histocompatibility complex 
MDR-TB multi drug resistant tuberculosis 
MIRU-VNTR MIRU variable-number tandem repeats 
MMR macrophage mannose receptor  
MPT secreted mycobacterial protein 
MTC M. tuberculosis complex  
M Macrophage 
NGO non-government organisation 
NIPH Norwegian Institute of Public Health 
NO nitric oxide  
NSDP NGO service delivery program 
NTM non-tuberculous mycobacteriae 
NTP national TB program 
OR odds ratio 
PAS para-aminosalicylic acid  
PCR polymerase chain reaction 
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PE proline-glutamic acid motif protein family  
PGG principal genetic group 
PGRS polymorphic repetitive sequences 
PHC primary health care 
PMTR polymorphic tandem repeats 
PPE proline-proline-glutamic acid motif protein family 
PZA or P Pyrazinamide 
RD regions of differences 
RFLP restriction fragment length polymorphism  
RMP or R Rifampicin 
RNA ribonucleic acid 
RNI reactive nitrogen intermediates  
ROM reactive oxygen intermediates  
rpoB  subunit of RNA polymerase gene 
SM or S Streptomycin 
ss- sputum-smear negative 
ss+ sputum-smear positive 
TB Tuberculosis 
TGF transforming growth factor 
Th T helper cell 
TLR toll-like receptor 
TNF tumour necrosis factor 
TS traditional strains 
TST tuberculin skin test 
UHC Upazilla Health Complex 
WHO World Health Organisation 
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SUMMARY 
 
Since the 1980ies a worldwide resurge of TB has taken place. There are indi-
cations that the current TB-situation represent a new pandemic of emerging success-
ful strains, and that it may take a different course from that observed previously, due to 
both host and parasite changes. This thesis aimed at contributing to the current know-
ledge that forms the fundament for local, national and international control of tubercu-
losis.  
 
Fingerprinting (Paper I): A total of 111 M. tuberculosis isolates from new pulmonary 
tuberculosis (TB) patients, living in the rural Sunamganj district in northern Bangladesh 
were characterized with IS6110 restriction fragment length polymorphism analyses 
and spoligotyping at the National Reference Laboratory for Mycobacteria at the Nor-
wegian Institute of Public Health (NIPH). Only 3 of the isolates belonged to the Beijing 
genotype of M. tuberculosis. A high degree of diversity indicated that the spread of M. 
tuberculosis, in this rural area, was not caused by closely related genotypes but rather 
represented a well established epidemic. The TB cases in the current study were less 
likely to represent recent transmission than what is commonly observed in the urban 
parts of south-east Asia. A majority of the strains belonged to the ancient East African- 
Indian (EAI) lineage, and the study was the first to describe the EAI6 BD1 sub-clade. 
More importantly, the different epidemic situation between urban and rural Banglade-
shi areas became obvious. Previous studies had demonstrated the abundance of the 
Beijing lineage of M. tuberculosis in Dhaka [4], yet in the current study the EAI repre-
sented a well established epidemic. It was indicated that the TB cases of this isolated 
area in a high-incidence country, represented those of an established epidemic, not 
yet influenced by recently disseminated strains. 
 
Susceptibility testing (Paper II): Spread of drug-resistant TB threatens TB-control 
programs, and all countries need to monitor the patterns and trends of anti-TB drug 
resistance. Such data assess the quality of control programs and help forecast future 
trends of drug resistance. It may also help establish guidelines for TB therapy in given 
settings. Among the current collection, 95 isolates of M. tuberculosis represented 
those from sputum-smear microscopy positive (ss+) patients. These isolates were 
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tested for susceptibility to streptomycin (SM), isoniazid (INH), rifampicin (RMP) and 
ethambutol (EMB) at the NIPH. The total resistance among new cases to any drug 
was 31%. For SM it was 18%, INH 23%, RMP 2%, EMB 10% and 2% were multidrug-
resistant (MDR). The National Tuberculosis Program (NTP) in Sunamganj is still effec-
tive, although the high resistance to INH is alarming. An increased risk of treatment 
failure has been demonstrated in areas with high levels of INH resistance, and a high 
proportion of INH resistant cases may develop resistance to RMP during treatment. 
 
Diagnostic Delay (Paper III): Early diagnosis and immediate initiation of treatment 
are essential for an effective TB control program. Delay in diagnosis is significant to 
both disease prognosis at the individual level and transmission within the community. 
Most transmissions occur between the onset of cough and initiation of treatment. A 
review of 58 studies addressing delay in diagnosis and treatment of TB was per-
formed. We found different definitions of, for example, debut of symptoms, first appro-
priate health care provider, time to diagnosis, and start of treatment. Rather than ex-
cluding studies that failed to meet strict scientific criteria (like in a meta-analysis), we 
tried to extract the "solid findings" from all of them to arrive on a more global under-
standing of diagnostic delay in TB. The main factors associated with diagnostic delay 
included human immunodeficiency virus; coexistence of chronic cough and/or other 
lung diseases; negative sputum smear; extrapulmonary TB; rural residence; low ac-
cess (geographical or sociopsychological barriers); initial visitation of a government 
low-level healthcare facility, private practitioner, or traditional healer; old age; poverty; 
female sex; alcoholism and substance abuse; history of immigration; low educational 
level; low awareness of TB; incomprehensive beliefs; self-treatment; and stigma. The 
core problem in delay of diagnosis and treatment seemed to be a vicious cycle of re-
peated visits at the same healthcare level, resulting in non-specific antibiotic treatment 
and failure to access specialized TB services. Once generation of a specific diagnosis 
was in reach, TB treatment was initiated within a reasonable period of time. 
 
A systematic recording of diagnostic delay can be utilized as a tool to monitor 
the infectious pool of tuberculosis in a population (Paper IV): One out of two 
goals of TB control programs is to stop transmission of M. tuberculosis. However, this 
can not be rapidly accomplished, because in endemic areas most of the population is 
already infected, serving as a reservoir that continuously contributes to the pool of in-
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fectious cases. Tuberculin surveys are the main tools used to monitor the infectious 
pool, but there are serious methodological constraints, and they require resources and 
expertise that are often unavailable. There is an urgent need for alternative means to 
monitor the epidemic at the local level. We investigated if a systematic registration of 
treatment delay in the tuberculosis program records of the Amhara Region of Ethiopia 
could be utilized to estimate the infectious pool of TB. By recording the treatment de-
lay for new TB cases, retreatment cases and failures, and by estimating the number of 
undiagnosed cases, the total number of infectious days and hence an estimate of the 
infectious pool could be calculated. Of these categories, new sputum smear-positive 
TB cases contributed the greatest number of infectious days. A local TB program can 
use a systematic recording of treatment delay as a quantifiable variable to monitor the 
infectious pool, and can also serve as an indicator of program performance. 
 
Interferon-gamma based Assay in the Diagnosis of tuberculosis infection after 
short-time Exposure of Health Care Workers (Paper V): Substantial resources are 
utilized to follow up personnel after unprotected exposure to patients with sputum-
smear positive pulmonary tuberculosis in Norwegian health care institutions. Due to 
the low specificity of the Tuberculin Skin Test (TST), a large proportion of the group 
defined as super-infected after exposure are probably false positives, which may lead 
to  incorrect treatment, waste of resources, and unnecessary anxiety. However, re-
cently developed interferon- release assays based on the M. tuberculosis specific 
ESAT-6 and CFP10 antigens may improve specificity significantly. A total of 155 
health care workers exposed to TB at three Norwegian hospitals as well as a non-
exposed control group of 48 individuals were tested with both TST and the interferon- 
test T-SPOT.TB. Within the exposed group 42 individuals (27 %) were TST positive, 
while no more than 5 (12 %) of these had a positive T-SPOT.TB test. However, only 
27 individuals were new TST positives after recent exposure, of whom 3 (11%) dem-
onstrated a positive T-SPOT.TB test. All individuals in the control group were T-
SPOT.TB negative, but three persons were found TST positive. Our data indicate that 
the frequency of latent TB in the total cohort of health care workers is low, as is the 
rate of transmission of TB to exposed individuals.  
 14 
 
       
 
Synthesizing World Maps showing absolute (diameter) and percentage (colour) numbers of 3 genotype fami-
lies within each country: Beijing; EAI (East-African Indian) CAS (Central Asia). These maps were built on an 
updated SpolDB4 on 2005 September 14
th
, on clusters of the 50 most frequent shared types for a total of n = 
17212 isolates (Beijing n = 4042, EAI n = 1684, CAS n = 1022). Brudey et al. BMC Microbiology 2006 
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1. INTRODUCTION 
1.2 THE GLOBAL EMERGENCY 
Since the 1980ies a worldwide resurge of tuberculosis (TB) has taken place. 
There are indications that the current TB-situation represent a new pandemic and that 
it will take a different course from that observed previously, due to both host and para-
site changes.  
A family of M. tuberculosis that later received great attention was first de-
scribed among isolates from the Beijing region of China. This particular genotype was 
demonstrated in >80% of the TB patients there in 1995 [7].  Soon reports of domi-
nance of strains belonging to the Beijing Lineage (BL) appeared from various parts of 
the world (above map). For example in the Archangel oblast, Russia (1998-1999), 
Toungoussova et al. found that 44.5% of the strains belonged to the BL [8], and in the 
prisons 76% of the isolates were assigned to BL [9]. A total of 43.4% of the isolates of 
the BL were multidrug-resistant (MDR), compared to 10.6% MDR among the tradi-
tional strains. A total of 92.5% of the BL were part of a cluster, compared to 33.3% of 
the traditional strains. A higher rate of clustering and also a younger age among the 
BL strain patients indicated a higher degree of recent transmission. BL infections were 
also more commonly isolated from alcohol abusers and from patients with chronic ob-
structive lung disease. In 1990-93 strains of the “W-family” caused a large outbreak of 
drug resistant TB in New York [10]. It was later demonstrated that the “W-family” was 
identical to the BL. In this context it must be remembered that other M. tuberculosis 
lineages dominate in other parts of the world, and are related to clustering, drug re-
sistance and other virulence related characteristics [11].   
It has been emphasised that the BL is a heterogeneous group, and the clinical 
presentations vary between different geographical settings, featuring variable degree 
of virulence, drug resistance, host populations and clustering [12-16]. Currently, it is 
not clear whether the observed variability is a function of the BL population of particu-
lar geographical settings, or a function of the genetic composition of the human popu-
lation, or a combination of these two variables. To explain the key role of the BL in the 
current global pandemic three main qualities of this lineage of strains have been out-
lined: 
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Firstly, there is increasing evidence that a majority of BL strains have in-
creased virulence compared to other lineages [16]. Compared to other common M. 
tuberculosis families there are studies indicating that members of the BL has an in-
creased expression of the phenolic glycolipid PGL-tb associated with a less efficient T 
helper cell 1 (Th1) response [17, 18]; a preference of inducing interleukin-4 (IL-4) and 
IL-13, which characterize Th2 polarized immunity (non-BL induce more IL-12 and INF-
 associated with phagocyte activation and Th1 protective immunity) [15, 19]; a de-
creased apoptosis of infected macrophages (Ms) (associated with protection)  and 
increased apoptosis of Th1 cells (associated with aggravation) [20]; an increased 
ppe44 expression associated with a higher virulence [21]; an increased expression of 
alpha-crystallin and decreased expression of Hsp65, PstS1, and the 47 kDa, all asso-
ciated with increased virulence [22]. 
Secondly, as in Archangel and many (but not all) geographic areas where BL 
strains are frequent, they more frequently possess drug resistance than non-BL strains. 
A review of studies on the worldwide occurrence of BL found associations with drug 
resistance to be variable: only 4 of 12 studies reported statistically significant in-
creases in the proportions of drug resistance among Beijing strains [16]. Among the 
Asian studies only one found a statistically significant increase in drug resistance in BL 
[16], and in Hong Kong BL were less likely than the others to be isoniazid resistant [23]. 
In New York, Cuba, and Estonia BL were strongly associated with drug resistance [24-
26].  In given areas some members of the BL are strongly associated with resistance 
in not previously treated individuals, and cause clusters ten times as big as other 
strains [16, 27]. It is known that many bacteria develop drug resistance at the cost of 
fitness [28]. Drug resistant strains that experience competitive pressure from suscep-
tible strains may loose their advantage if the selective antibiotic is no longer present in 
the environment. In the absence of the drug, the susceptible bacteria may have a sur-
vival advantage because they do not have to spend energy to circumvent the drug 
block in their metabolism. After a time, then, they may out-compete the resistant mi-
crobes. However, some RMP resistant strains of the BL exhibit similar growth rates as 
other sensitive BL [29]. Furthermore, fitness cost associated with the evolution of re-
sistance to rifampin in M. tuberculosis may be different in clinical isolates compared to 
in vitro-generated mutants. An atypical Beijing strain demonstrated the ability to 
spread despite acquiring resistance to RPM. Transmission was linked to human im-
munodeficiency virus coinfection, raising concern for the spread of drug resistance in 
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vulnerable populations [30]. Another study found that BL strains have an increased 
acquisition of drug resistance and rapid adaptation to the environment as the conse-
quence of increased single-nucleotide polymorphisms (SNPs) in the mismatch repair 
genes [31].  
A well organised TB control program with a high level of treatment completion 
may control epidemics of  M. tuberculosis, whether they belong to the BL or not [16]. 
Unfortunately, TB control programs in some high-incidence countries apparently do 
not receive necessary political commitment. Microbiological services are weak in many 
areas with high rates of TB. Primary drugs are often used in cases that are already 
resistant, because drug susceptibility tests are not available. Such practices acceler-
ate the development of resistant M. tuberculosis populations and may eventually lead 
to epidemiological situations of catastrophic dimensions.  
Third, recent studies from Vietnam indicate that Mycobacterium bovis BCG 
does not induce protective immunity towards the BL [32, 33].  Experimental animal 
studies from Mexico and USA indicate the same for given isolates of the BL [34-36]. M. 
bovis BCG still represent the only available vaccine against TB, if escape variants of M. 
tuberculosis exist the urgency of the global TB situation is clearly underscored.  
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1.3 THE EVOLUTION OF M. TUBERCULOSIS 
1.3.1 TB evolution and aetiology 
Humans have been challenged by mycobacterial infections for thousands of 
years. It is believed that the genus Mycobacteriumoriginated more than 150 million 
years ago [37]. Communicable diseases require host populations that comply with 
their required critical community size (CCS). The CCS is the number of potential hosts 
that need to live in a community if an infectious disease is to exist within it. Although 
not yet epidemic, an early progenitor of M. tuberculosis was probably infecting homi-
nids in East Africa three million years ago [6]. It has been calculated that the currently 
known members of the M. tuberculosis complex (MTC) originated from a hypothetical 
common progenitor about 15,000 - 35,000 years ago [6]. It is commonly believed that 
this bacterial evolution coincided with the establishment of agricultural communities 
and that communicable M. tuberculosis found its CCS in the early human societies. 
Scheme of the evolutionary pathway of the tubercle bacilli illustrating suc-
cessive loss of DNA in certain lineages 
 
 
 
Brosch et al. (2002). With kind permission from Proc. Natl. Acad. Sci.  
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Tuberculous skeletal lesions have also been identified by archaeologists at various 
sites all over the world [38].   
The genus Mycobacterium is divided into two main groups. The MTC and 
non-tuberculous mycobacteria (NTM), often called environmental mycobacteria [39]. 
The NTM group is genetically heterogeneous, and include the M. avium complex as 
well as a wide range of other species. They can be isolated from environmental sour-
ces like soil and water, are usually non-pathogenic for immuno-competent humans, 
and are often the source of false positive tuberculin skin tests (TST), which can be de-
fined as e.g. a TST > 10 mm not caused by members of the MTC.  
The species of the MTC include M. tuberculosis, M. bovis (including the at-
tenuated BCG strains), M. microti, M. canettii and M. africanum [40]. It was long be-
lieved that M. tuberculosis developed as a result of M. bovis crossing the species bar-
rier from cattle to humans, after humans domesticated wild animals. Recent phylogen-
etic studies however, show that 20 known regions of difference (RD) did not occur as 
results of spontaneous site mutations, but rather represent ancient, irreversible genetic 
events that apparently have taken place in common progenitor strains [40]. The struc-
ture of the phylogenetic tree is mainly based on deletions rather than mutations and 
gene acquisitions. Based on the presence or absence of a M. tuberculosis specific 
deletion (TbD1), the strains are divided into “ancestral” or ‘‘modern’’. Because the ori-
ginal habitat of Mycobacteria apparently was soil or water a number of genes needed 
for these environments became “surplus” as the main hosts ended up to be humans 
and other mammals. The evolution can bee seen as a comprehensive process to de-
lete these no longer useful genes [6]. Wirth et al. obtained new insights into the origin 
of MTC and its dynamic association with the human host. By using mycobacterial tan-
dem repeat sequences as genetic markers, they showed that MTC consists of two in-
dependent clades; M. tuberculosis lineages from humans, and M. tuberculosis lin-
eages from both animals and humans. The latter was also likely derived form a human 
pathogenic lineage, supporting the hypothesis of an original human host. They pro-
vided important genetic evince indicating that the most common ancestor of the bacte-
rial complex emerged some 40,000 years ago from its progenitor in East Africa, the 
region from where modern human populations disseminated around the same period 
[41]. 
Based on analysis of partial gene sequences of katG and gyrA, Sreevatsan et 
al. defined three subgroups among the “modern” strains of M. tuberculosis. Group 
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1 include the BL and have the katG463 CTG (Leu) and gyrA95 ACC (Thr) mutations,  
Group 2 that include the Haarlem lineage and Africa clusters carry a katG463 CGG (Arg) 
mutation, in addition to the gyrA95 ACC (Thr). Group 3 that include the H37Rv strain 
also carry a katG463 CGG (Arg) mutation but also exhibit a gyrA95 AGC (Ser) mutation 
[42]. In “ancestral” strains, where the TbD1 region is not deleted, Leucine (CTG) is 
found at katG463. It is possible that during the evolution of M. tuberculosis, the katG 
mutation at codon 463 (CTG (Leu)  CGG (Arg)) occurred in a progenitor strain that 
had already deleted the TbD1 [40, 43].  
The evolution of M. africanum, M. microti, and M. bovis have been found to be 
the result of the loss of DNA in the Region of Difference 9 (RD9) that diverged from 
the hypothetical progenitor strain prior to the deletion of the TbD1. It is therefore un-
likely that M. tuberculosis evolved from M. bovis. Since M. canettii and ancestral M. 
tuberculosis strains harbour both TbD1 and RD9 it is reasonable to believe that they 
represent descendants of tubercle bacilli that existed prior to the divergence of the M. 
africanum/M. bovis lineage. Principally, the only thing we know about “ancestral” 
strains is that they no longer exist, but we can anticipate that the common ancestor of 
the tubercle bacilli resembled M. tuberculosis or M. canettii and was possibly already a 
human pathogen [40].  
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1.3.2 Molecular biology and epidemiology 
According to 16S rRNA studies the genus Mycobacterium belongs to the acti-
nomycete branch of Gram-positive bacteria. Typically, mycobacteriae unlike other 
members of the group lack a spore stage in the life cycle. The majority of the actino-
mycetes are soil-dwelling and non-pathogenic organisms. M. tuberculosis also prob-
ably lived in the soil before it was specialized to its human host [38, 44]. 
In 1998 the complete genome sequence of M. tuberculosis  H37Rv was pub-
lished [45], and later the genomes of several other strains have been sequenced. Util-
izing microarrays, Behr et al. identified 14 regions (RD1-14) that were present in 
H37Rv but absent in M. bovis BCG Pasteur, and two regions (RD15 and 16) that were 
found in only some BCG strains. The deleted regions included many genes of un-
known functions but also genes that coded for several known proteins such as the 
ESAT-6 secreted antigen and CFP-10 phospholipase C [46]. M. tuberculosis was 
found to have 4,411,529 bp on the circular genome that contains 3,924 open reading 
frames. Based on similarity to known genes, 40% had confidently assigned functions, 
44% a probable function and 16% were left as orphan genes with no known function in 
1998 [46].  
M. tuberculosis has more than 250 genes devoted to lipid and polyketide me-
tabolism, suggesting that it has a lipolytic lifestyle in vivo. Before entering into the 
dormant state, M. tuberculosis accumulates lipids originating from the host cell mem-
brane. When reactivated, these lipids are hydrolysed and they start to multiply. In ac-
tive disease, degradation of both extra and intracellular lipids is a key issue, which was 
ignored for a long period due to difficulties in obtaining high expression levels of lipo-
lytic enzymes. The completion of the M. tuberculosis  genome offered a new oppor-
tunity to these kind of studies [47].  
Surprisingly, the genome also contains several genes encoding for enzymes 
needed for anaerobic metabolism like nitrate- and fumarate reductase, which is unex-
pected considering the aerobic nature of M. tuberculosis. The explanation is that when 
oxygen is slowly depleted from growing cultures of M. tuberculosis, they enter a dor-
mant state seen with latent TB. Sohaskey et al. found that in this hypoxic state, nitrate 
reductase activity is strongly induced [48].  
About 10% of the genome codes for 99 members of the Proline-Glutamic acid 
motif (PE) protein family and 68 members of the Proline-Proline-Glutamic acid motif 
(PPE) family. The genes coding for these families contain polymorphic repetitive se-
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quences, PGRSs (PE) and polymorphic tandem repeats, PMTRs (PPE).  Their func-
tion is mostly unknown, but it is believed that they are involved in generating antigenic 
variation and disease pathogenesis. There is evidence that the expansion of the PE 
and PPE gene families is linked to the duplications of the ESAT-6 gene clusters. 
Members situated in and associated with ESAT-6 represent the most ancestral copies 
of the PE and PPE gene families. Their emergence is a recent evolutionary event [49], 
occurring at defined branching points in the evolution of the Mycobacterium genus, 
and are only present in multiple copies in the members of the MTC and close relatives 
[49].  
Several proteins have been identified that may act as potential virulence fac-
tors including phospholipases C [50], lipases and esterases [51]. Proteins involved in 
metabolism and storage of oxygen, carbon and iron have also been identified, and 
seem to be associated with pathogenetic processes that facilitate the entry, replication, 
and persistence of M. tuberculosis in its host [52].  
There are four copies of the mycobacterium cell entry (mce) operon in the ge-
nome. The mce gene was originally characterized as a M-colonizing factor in M. 
tuberculosis. Six mammalian cell entry proteins (Mce3A-F) encoded by the mce3 op-
eron are expressed during in vitro growth of M. tuberculosis [53].   
 
1.3.3 Molecular fingerprinting methodologies utilized                         
for M. tuberculosis  
As long as TB is not under control, it becomes increasingly urgent to monitor 
the epidemiology both at regional, national and local levels. Knowledge on the epi-
demiology of M. tuberculosis is crucial in order to control the disease. Analysis of TB 
transmission patterns and other aspects in TB epidemiology improved tremendously 
after the introduction of DNA fingerprinting of M. tuberculosis. Until the 1990s, anti-
biotic susceptibility patterns and phage typing were used for M. tuberculosis strain 
identification, but these methodologies have significant limitations. The discovery that 
the patterns of certain transposable elements in the M. tuberculosis genome can be 
utilized for strain identification has proven to be superior to the more traditional tech-
niques, particularly in outbreak investigations [9, 54]. Repetitive DNA elements in M. 
tuberculosis were recognized independently by Eisenach [55] and Zainuddin and Dale 
[56].  
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The most widespread and robust genotyping tool, used to discriminate or sub-
speciate clinical isolates of M. tuberculosis is the insertion sequence (IS) 6110 restric-
tion fragment length polymorphism (RFLP) [57]. By use of IS6110 RFLP one can type 
the M. tuberculosis  isolates on the basis of the number and position of IS6110 [57]. In 
our Sunamganj study IS6110 RFLP was utilized as the main fingerprinting tool.  
Spoligotyping is based on the in vitro amplification of the DNA of the highly 
polymorphic Direct Repeat (DR) genomic locus present in the M. tuberculosis chromo-
some. In our study spoligotyping was used to differentiate isolates that carried less 
than 5 copies of IS6110 and to identify members of the various M. tuberculosis lin-
eages [58].  
The main description of these two methodologies is found in section 2.2.6. 
 
 
OTHER FREQUENTLY USED FINGERPRINTING METHODS 
 
MIXED-LINKER PCR 
DNA is digested with the HhaI restriction enzyme, and a double-stranded oligonu-
cleotide linker is ligated to the ends of the restriction fragments. The name “mixed linker” 
comes from the use of two oligonucleotides where uracil is substituted for thymidine. This step 
is followed by PCR with an IS6110-specific oligonucleotide primer and a linker primer. The 
sequence of the linker primer is identical to that of the thymidine-containing strand of the linker 
except that it lacks the two nucleotides complementary to the 3' overhang created by restric-
tion with HhaI. The main advantage of mixed-linker PCR fingerprinting over the traditional 
RFLP method is its independence from mycobacterial growth, where RFLP requires 2-3 
weeks of cultivation. A fingerprint could be obtained directly from a single colony of the primary 
isolate without further culture. In an outbreak situation, a specific RFLP type should correlate 
well with the drug resistance pattern of the isolates, and rapid typing of the isolate might be 
used to design the treatment regimen [59].  
A further development of this method, called fast ligation-mediated PCR (FLiP) al-
lows analysis of strains within one working day, and starts from less than 1 ng of mycobacte-
rial DNA or a crude cell lysate. Blinded analysis showed the ability to differentiate 81 types 
among 90 MTC isolates with 84 different IS6110 RFLP patterns. FLiP is suggested to serve as 
a method to rapidly detect chains of transmission prior to starting time-demanding standard 
IS6110 RFLP [60]. 
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MIRU-VNTR  
Based on the above mentioned polymorphic tandem repeats of the PPE region the 
variable-number tandem repeats fingerprinting methodology (MIRU-VNTR) has been devel-
oped. Twelve mycobacterial interspersed repetitive unit (MIRU) loci were initially amplified and 
the amplicons were analyzed by agarose gel electrophoresis to determine the copy number at 
each MIRU locus. In some studies MIRU-VNTR has produced more distinct patterns than 
IS6110 RFLP or spoligotyping. [61].  
 
AFLP and FAFLP 
Amplified fragment-length polymorphism (AFLP), or its fluorescent version FAFLP, is 
a PCR-based fingerprinting technology. The first step of AFLP/FAFLP is to cut the whole M. 
tuberculosis genome into fragments utilizing restriction enzymes. The next step is ligation of 
adaptors complimentary to the restriction sites and selective PCR amplification of a subset of 
the adapted restriction fragments. These fragments are finally visualized on denaturing polyac-
rylamide gels either through autoradiographic or fluorescence methodologies (FAFLP). The 
availability of many different restriction enzymes and corresponding primer combinations pro-
vides flexibility, enabling AFLP/FAFLP to be utilized for a multitude of tasks like polymorphism 
screening, quantitative trait locus (QTL) analysis and genetic mapping. Although conflicting 
experiences exist (Ulf R. Dahle, personal communication), compared to other fingerprinting 
methods some authors report that AFLP/FAFLP provides equal or enhanced performance in 
terms of reproducibility and resolution [62, 63]. 
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Reproducibility and number of types obtained by using various DNA typ-
ing methods for differentiation of mycobacterial strains  
 
 
 
 
Kremer 1999 [5], Kremer 2005a [6] 
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As molecular fingerprinting was introduced, basic assumptions had to be 
changed. By identifying identical fingerprints, transmission could be traced from case 
to case and outbreaks with clusters of identical fingerprints could be discovered. It was 
for example previously thought that a majority of TB cases in Western Europe come 
from reactivation of remote infection [64]. Using fingerprinting, de Viedma et al. found 
that 33% of patients with reoccurring TB in Spain was due to reinfection with a new 
strain rather than reactivation [65]. Another example is the intensified effort to control 
the rapid spread of MDR-TB. To identify the strain patterns and thus be able to ana-
lyze the patterns of transmission is a basic need of a good TB control program. Gen-
erally, DNA-fingerprinting is useful to 
 
1. identify laboratory contamination 
2. Identify and decipher outbreaks 
o differentiate between reactivation and reinfection 
o determine risk factors for transmission 
o evaluate preventive measures 
3. perform surveillance of transmission, both nationally and internationally  
 
These three usages of DNA-fingerprinting are not further described in the text, as this 
would demand voluminous space and is beyond the scope of this thesis. 
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1.4 THE HUMAN HOST 
 
The human host’s response to infection with M. tuberculosis 
 
From Kaufmann and Hahn: Mycobacteria and TB.  Karger 2003 (with permission)  
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1.4.1 Pathology and Natural history of infection 
Fortunately, the human immune system generally controls efficiently the vast 
majority of infections. As illustrated above, in the case of TB there are three possible 
outcomes of the primary, early infection [66]:  
1. M. tuberculosis is eradicated; abortive infection. This is a mechanism that has 
yet not been proven, but probably accounts for a proportion of infected people.  
2. Containment of infection, or the establishment of latent infection; accounts for 
>90% of the cases.  
3. Primary TB.  
Infection with M. tuberculosis  is the result of inhalation of airborne droplet nu-
clei that are generated when individuals with active pulmonary TB cough [67]. On their 
way through the bronchial tree, the droplets have to pass several kinds of physical 
barriers like the nasal conches and the ciliated and delicately distributed bronchial tree 
before a few bacilli finally may reach the alveoli and are engulfed by the alveolar Ms, 
and subsequently as they spread through the lymphatic system, the bacilli are also 
engulfed by dendritic cells in the regional (mediastinal and hilar) lymph nodes, where 
the major part of antigen presentation takes place [68].  
The immune response seems to be depending on the type of receptor M. tu-
berculosis utilizes to enter the host cell. Entry of IgG-opsonized mycobacteria via FcR 
receptors results in activation [69], while entry via complement receptor 3 (CR3) does 
not activate the cell properly [70]. Other receptors that take part in the engulfment is 
the M mannose receptor (MMR), surfactant protein receptors, cluster of dif-
ferentiation 14 (CD14) pattern recognition receptor, and toll-like receptors 2 and 4 
(TLR2 and TLR4) [71]. 
However, also neutrophils play an active role in the first innate immune re-
sponse. The idea that neutrophils are able to kill mycobacteria is supported by some 
studies [72], but not by others [73]. But the function of neutrophils goes beyond their 
microbicidal ability. It is believed that they contribute to the control of infection through 
the production of chemokines [74], take part in the induction of granuloma formation 
[75] and transference of their own microbicidal agents such as human neutrophil  -
defensins and cathelicidins to infected Ms [76].  
As fragments of M. tuberculosis peptides are presented to T helper cells 
through the major histocompatibility complex II (MCH II) on the surface of the Ms or 
dendritic cells, a strong, specific Th1 response of cell-mediated immunity is triggered. 
 29 
The indifferent T helper cells (Th0) are stimulated to become Th1 cells under the influ-
ence of signal substances like interleukin 12 (IL12) that are secreted by activated Ms. 
On stimulation, Th1 cells excrete interferon- (INF- ), interleukin 2 (IL2) and tumour 
necrosis factor- (TNF-) that further reinforce a strong, cell-mediated Th1 immune 
response [77]. Th1 type responses are essential to protection against intracellular 
parasites. In contrast, Th2 responses, which are characteristic of allergic disorders 
and helminth infections, are rather believed to be responsible for immunopathology, 
and thus active disease for infections with intracellular pathogens [78]. The current 
view is that TNF-/IFN- activated Ms are able to effectively eliminate intracellular 
pathogens, and that IL-4 and IL-10 suppress M activation and thus parasite clear-
ance. The different types of responses also negatively influence each other with IL-4 
favoring the development of Th2 and IL-12 the development of Th1 type cells. The 
INF- produced by Th1 cells directly inhibits the development of Th2 type cells [79].  
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 Ultimately, most M. tuberculosis bacilli are killed within the Ms. But M. 
tuberculosis has developed a range of mechanisms to evade the immune response, 
and in some cases the Ms fail to kill the bacilli. On the contrary, the Ms become 
sanctuaries where M. tuberculosis survive and even multiply [80]. In the murine model 
of Mustafa et al. mycobacterial antigens were concentrated to 3-6 % of the Ms in 
lung granulomas [81]. 
A crucial effector pathway of protective immunity is nitric oxide (NO) and its in-
termediates. It is both the major bactericidal substance of the lysozyme and has an 
important signalling and second messenger function. NO-knock-out mice that are in-
fected with M. tuberculosis develop an aggravated disease. NO is transformed into 
highly cytotoxic reactive nitrogen intermediates (RNI) by the enzyme NOS2. M. tuber-
culosis actively blocks the action of NOS2, thus inhibiting the production of RNI [82].  
The role played by the reactive oxygen intermediates (ROM) during infection 
has not been explained completely, though it is known that hydrogen peroxide pro-
duced by Ms activated by cytokines has a mycobactericidal activity. Also, it has been 
found that the tubercle bacillus presents molecules such as lipoarabinomannam (LAM) 
and phenolic glycolipid I, which work as oxygen radical scavenger molecules [83]. 
Not only is the NO pathway inhibited. The term “fortress M. tuberculosis” has 
been used to describe the antioxidant complex of M. tuberculosis. The complex con-
sists of substances that are actively secreted by M. tuberculosis to protect it self from 
being phagocytized, like dihydrolipoamide dehydrogenase, thioreductin-like AphD, 
NAD dependent peroxidase, dihydrolipoamid succinyltransferase, peroxinitrite reduc-
tase, dihydrolipoamid succinyltransferase, truncated haemoglobin and AhpC peroxire-
doxin [84].  
M. tuberculosis has also developed mechanisms to survive within the 
phagosome. Among the strategies is to inhibit the H+-ATPase that pumps H+ into the 
phagosome, thus making it less acidic and hostile [85, 86]. Another strategy is to in-
hibit the maturation of the phagosome by utilizing the surface polysaccharide mannose 
capped mannosylated lipoarabinomannam (ManLAM) to block the early-endosomal 
autoantigen 1 (EEA1), which binds phosphatidylinositol-3-phosphate, a Rabankyrin 5 
(Rab5) effector that is required for endosome fusion [87]. The fusion of M. tuberculosis 
with the lysosome is also inhibited by modulating soluble N-ethylmaleimide-sensitive 
factor attachment receptor (SNARE) proteins, thus inducing accumulation of trypto-
phan-aspartate containing coat protein (TACO) [85, 88]. When Ms were made  
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TACO-deficient experimentally, the maturation of mycobacterial phagosomes 
was not arrested and therefore these cells were able to eliminate bacilli by fusion of 
phagosomes with lysosomes [89]. TACO binds itself to the plasmatic membrane of 
Ms through cholesterol, which also plays an important role in mycobacterial uptake 
by Ms [90].  
Another important defence mechanism is to avoid a specific immune re-
sponse by inhibiting the expression of M. tuberculosis antigens through the MHC II 
complex on the surface of the Ms. Two secreted peptides, one of 19 KDa and one of 
25KDa, execute a direct inhibition of the Toll-like 2 (TL2) surface receptor, that is cru-
cial to the development and excretion of the MHC II complex (named exosome in the 
above figure)  [91].  
There is also evidence that M. tuberculosis evades the immune system by 
choosing non-professional phagocytes as host cells. In a study of necropsy specimens 
from people who died from other reasons than TB, mycobacterial DNA was detected 
in Ms, type II pneumocytes, fibroblasts, and endothelial cells [92]. Other studies have 
confirmed that endothelial cells [93] and fat cells [94] can host M. tuberculosis bacilli 
and allow them to replicate. On the other hand, epithelial cells also seem to be able to 
initiate a pro-inflammatory immune response, e.g. by secreting IL-8 [95] or inducing 
the production of NO [96]. 
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As the TB granulomas matured in the murine model of Mustafa et al., they 
acquired a distinct morphology. However, there was a striking lack of lymphocytes  
surrounding the infected Ms, and the frequency of apoptotic cells was high [80]. It is 
demonstrated that M. tuberculosis has evolved several evasion mechanisms to with-
stand the hostile environment of Ms, but how does the infected Ms escape from the 
cytotoxic T-cells? Mustafa et al. found that M. tuberculosis infected Ms strongly ex-
pressed Fas ligand (FasL), indicating that a mycobacterial infection can induce an in-
creased expression of FasL in the infected Ms. Ms, like almost all cells express Fas, 
and even if they fail to kill engulfed bacteria, the  Ms will express bacterial antigens, 
and thus become susceptible to cytotoxic lymphocytes. As M. tuberculosis induces the 
expression of FasL in the Ms, apoptosis will be induced in the Fas-expressing sensi-
tized lymphocytes. Thus, the epithelioid cells and the multinucleated giant cells (which 
are metamorphotic Ms) by virtue of the increased expression of FasL may make the 
granulomas an immune privileged site for mycobacteria [97] . 
 
 
 
1.4.2 The Koch’s phenomenon  
Among the first to study the pathogenesis of TB was Robert Koch, who inocu-
lated guinea pigs with TB to establish infection. After 4-6 weeks he once again injected 
them intradermally with TB culture filtrate. He then observed what has later been 
named the Koch’s phenomenon (KP); a necrotizing, inappropriate  response pattern 
Th1 
Confined, small granulomas Caseous necrosis, chronicity 
Mixed Th1/Th2 
after ~ 50 days 
The Koch’s phenomenon 
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[98], which is also the typical immunopathological response pattern in humans [99]. 
Studies of the human immune response to M. tuberculosis infection have demon-
strated that almost all immunocompetent individuals start out with a strong, completely 
Th1-dominated cellular response that is comprehensive, and leads to the containment 
of the M. tuberculosis bacilli in confined granulomas, which is typical for latent infection. 
However, if the infection progresses to primary active disease, after approximately fifty 
days there is a marked shift towards a mixed Th1/Th2 response that results in a 
necrotizing lung tissue damage dominated by caseous necrosis, caverns and chro-
nicity. The same pattern is seen in the case of reactivation of latent disease. It is not M. 
tuberculosis itself that causes the severe damage, but the human host’s inappropriate 
immunological response to it [99]. There is evidence that pro-Th1 cytokines like IL-12, 
TNF- and INF- may not only facilitate granuloma formation and bacillary elimination, 
but may also cause the local tissue necrosis typical of the KP, and systemic effects 
such as fever and wasting, due to the release of TNF- into the circulation [100]. At 
the same time anti-inflammatory cytokines such as IL-10, tumor growth factor beta 
(TGF-) and IL-4 down regulate the immune response and limit tissue injury by inhibit-
ing an incomprehensive inflammatory response. These cytokines, if produced in ex-
cess, may result in failure to control infection resulting in widely disseminated TB. It is 
the balance between the pro-inflammatory and anti-inflammatory immune responses 
that determines the outcome of the TB infection. In the phase of the mixed Th1/Th2 an 
increased INF- as against reduced TNF- probably suggests a better outcome [100]. 
In the murine model developed by Mustafa et al. a similar pattern of an initial asymp-
tomatic phase with a pure Th1 pattern and stable bacillary growth followed by a mixed 
Th1/Th2 phase of severe necrotizing lung pathology was seen [77].  
In the human host, once an inappropriate balance with local tissue ne-
crosis/KP is established, the imbalance does not correct itself during the natural 
course of the disease. Without appropriate treatment half of those with active pulmo-
nary TB die, and half of them survive with severe lung tissue damage [101]. The inap-
propriate mixed Th1/Th2 response also does not change back to the first comprehen-
sive pure Th1 response during treatment. This is one of the reasons why the standard 
treatment has to go on for at least six months. If treatment is discontinued at 3 months, 
relapse rates of up to 20% can be expected, even if sputum smears have become 
negative well in advance, and there are few surviving bacilli [99]. Graham Rook has 
postulated that if we could learn how to pace the immune response back to the first, 
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pure Th1 pattern, ultra-shortcourse chemotherapy regimens would be possible. Such 
an immunotherapy supported shortcourse could drastically reduce the efforts needed 
to treat each case of TB, and for the first time in history give perspectives of controlling 
or even eradicating the disease [99]. 
 
1.5 TREATMENT AND DRUG RESISTANCE 
1.5.1 Treatment 
Chemotherapy for TB became available in the 1940s with the introduction of 
streptomycin. Gradually the duration of therapy decreased from 18 months to currently 
6 months [102]. This happened in several steps: First the introduction of "triple ther-
apy" (Streptomycin (SM or S), Para-aminosalicylic acid (PAS) and Isoniazid (INH or H)) 
in 1952, which assured cure. The next step forward took place in the 1970s when it 
was discovered that INH in combination with Rifampin (RMP or R) could reduce the 
duration of treatment from 18 to 9 months. The final step towards only 6 months 
treatment was introduced in the 1980s by adding Pyrazinamide (PZA or Z) and 
Ethambutol (EMB or E) during the first two months [103]. A four drug regimen of INH, 
RMP, PZA and EMB for two months followed by  INH and RMP for four months 
(2HRZE/4HR) is currently the standard primary treatment drug regimen recommended 
by WHO [104].  
The included anti-TB drugs have different abilities and capacities to kill bacte-
Anti-TB drugs and drug resistance mechanisms 
 
Site of Action Antituberculous 
drug 
Genes associated Mutation  
frequency % 
Inhibition of nucleic 
acid synthesis 
Rifampicin rpoB >95 
    
Inhibition of protein 
synthesis 
Streptomycin 
 
rpsL, rrs (16S RNA) 
 
52-59 
 
 Amikacin/kanamycin rrs (16S RNA) 80 
    
Inhibition of cell wall 
synthesis 
Isoniazid katG, inhA, aphC, kasA, ndh 33-37 
 Ethionamide inhA 34 
 Ethambutol embCAB 39 
 Cycloserine alrA 46 
    
Unknown Pyrazinamide pncA 58 
    
Adapted from Hatfull and Jacobs [1] 
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ria, to sterilize different kinds of human tissues and to prevent the emergence of drug 
resistance. INH acts on metabolically active bacteria, and is the most potent drug re-
sponsible for the major early bactericidal activities of the 2HRZE/4HR regime [105, 
106].  
RMP has a potent sterilizing activity, and is the backbone of the regime. It not 
only acts on rapidly dividing bacteria as INH, but it also kills “persisters” in intermittent 
periods of metabolism. It can be said that the other drugs are RMP’s “bodyguards”; 
their major task is to prevent the emergence of RMP resistance, and especially the 
combination of INH and RMP is effective [107].  
PZA is also bactericidal, and has been added because it has a good sterilizing 
capacity by killing intracellular bacilli inside the Ms in an acid environment. EMB and 
SM are less potent drugs, EMB is probably bactericidal in high doses [108]. 
 
 
DOTS (Directly Observed Treatment, Short-course) has been presented as one of 
the most cost-effective health strategies available, and is both heavily supported by 
the World Health Organisation (WHO) and International Union Against Tuberculosis 
and Lung Disease (IUATLD) and utilized as the standard approach in most TB pro-
grams all over the world. DOTS implies that the drugs are taken by direct observation 
by a person that has been authorized by the NTP, usually a professional health care 
     
 
The DOTS strategy comprises five components [2] : 
 
(1) Political commitment for support to a strong national program. 
 
(2) Case-detection through sputum smear microscopy of all suspects coming to the 
general health services. 
 
(3) Directly observed treatment, with short-course therapy of all sputum smear-
positive patients 
 
(4) Regular and uninterrupted supply of anti-TB drugs. 
 
(5) A monitoring system for evaluation of treatment outcome. 
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worker. The DOTS strategy has three major goals: to treat patients already infected 
with TB, to prevent new infections and to avoid the development of drug resistance 
[109]. From 1995-2003 17 million patients were treated under the DOTS strategy, im-
plemented by 182 countries. An estimated 77% of the world's population lived in re-
gions utilizing DOTS with an average success rate (treatment completion) of 82% 
[110]. Globally, the rate of case detection, defined as the proportion of estimated new 
smear-positive cases notified by the NTP, reached 61% in 2006 (compared with the 
target of at least 70%) and the treatment success rate improved to 84.7% in 2005, just 
below the WHO Millennium target goal of 85% [111].  
However, a recently published Cochrane review of direct observed treatment 
(DOT) – the third component of the DOTS strategy - aimed to compare DOT with self 
administration of treatment [112]. Eleven trials with 5609 participants were included. 
No statistically significant difference was detected between DOT and self administra-
tion, neither with cure nor completion of treatment as endpoints. DOT provided at 
home compared with DOT provided at a clinic suggested a possible small advantage 
with home-based DOT. There was no significant difference in success rates between 
DOT supervised at a clinic versus by a family member or Health Care Worker (HCW), 
or for DOT provided by a family member versus a HCW. In conclusion, the review of 
randomized controlled trials conducted in low-, middle-, and high-income countries 
provided no support for DOT. In comparisonwith self administration DOT had no sig-
nificant effect on cure or treatment completion in people receiving treatment for TB. 
They concluded that DOT was unnecessary and disrespectful of patients [112].  
Obermeyer et al. performed an empirical evaluation of the DOTS strategy, and 
found that DOTS had no statistically significant impact on case detection in a wide 
range of models and specifications. Howver, DOTS population coverage had a signifi-
cant effect on overall treatment success rates in such a way that countries with full 
DOTS coverage benefit from at least an 18% increase in treatment success [113]. 
One of the main reasons for this seems to be geographical access for all to TB treat-
ment in DOTS covered areas. 
In their recent review of DOTS, Cox et al. found that the implementation of 
DOTS undoubtedly has improved the outcomes for millions of patients. However, they 
conclude that DOTS can only produce good outcomes reliably under "ideal" conditions, 
and can be of limited use in high burden settings, where challenges for the provision of 
even basic health services are manifold and complex [114]. 
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In defence of DOTS, Davies and Squire state that it is too soon to conclude on 
the efficacy of DOTS for treating TB [115]. WHO has also vigorously challenged reluc-
tant attitudes towards DOTS. It is argued that direct observation requires strong lead-
ership and a lengthy commitment of human resources, which is often not yet the re-
ality because of inadequate TB programs. The DOTS supporters have also launched 
principal arguments: it is believed that the ultimate ethical and legal responsibility for 
ensuring treatment completion and cure of a communicable disease belongs to the 
public health system and the community, and not to the individual patient [116]. 
Recent studies from Norway and Sweden also supports the use of DOTS. Nor-
way and Sweden are comparable societies except that Norway fully complies to the 
DOTS strategy, whereas Sweden does not. Transmission of TB is stable in Norway, 
despite the import of TB through immigration and an increasing TB incidence. Immi-
grants from regions with high rates of TB do not significantly contribute to the spread of 
disease in the resident population [117]. Serious shortcomings have been revealed in 
the Swedish TB control program, including massive spread of drug resistant M. tuber-
culosis in Stockholm [118]. The epidemiology of TB in the two countries is different. It 
seems likely that by introducing obligatory DOTS to all patients, Norwegian health per-
sonnel accomplish treatment in an increasingly diverse population. In Sweden, how-
ever, control is complicated by the lack of DOTS. This situation has been promoted as 
a strong argument for introducing DOTS in all countries where it has not yet been im-
plemented [119]. 
 
1.5.2 Drug resistance  
Rapid and accurate diagnosis of symptomatic TB is critical for the control of 
TB. The resurgence of TB worldwide has been accompanied by an increase in the 
incidence of MDR TB on all continents [120]. The introduction of efficient anti-TB drugs 
was inevitably followed by development of drug resistance. In M. tuberculosis, drug 
resistance does not occur by acquisition of new resistance genes, as described for 
many other bacteria, but by random mutations in chromosomal genes. These muta-
tions are spontaneous and do not depend on exposure to drugs [121]. For most drugs, 
the product of multiple genes constitutes the drug target and thus the sites for muta-
tions leading to resistance are plenary [122]. The striking exception in this situation is 
that RMP resistance is mediated by mutations in the single gene encoding the beta 
subunit of RNA polymerase (rpoB) only [123]. The development of resistance to a drug 
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in the bacillary population follows from positive selection of a very small number of 
spontaneously mutated individual cells. Thus, the development of multiple resistance 
is due to a “domino effect” of periods of practical mono- or oligo-therapy [124]. TB con-
trol has a very limited number of effective anti-TB drugs at hand. It soon became obvi-
ous that if bacilli developed resistance to both RMP and INH, termed multi-drug resist-
ance (MDR), successful treatment is difficult [100]. The treatment results have not im-
proved much over the years despite heavy investments in second line drugs. Since 
RMP is the cornerstone among the first line drugs and MDR often follows once this 
drug fails, the logical thing to do is to define RMP resistance as the condition needed 
to be addressed [125]. 
MDR-TB poses a most serious threat to TB control; however, the experience 
in some places has been more promising than expected. Some countries have man-
aged to prevent MDR in their TB population through strict drug policy [126]. But once 
MDR is established in the population, it is hard to curb it. The reason for this seems to 
rest partly in the DOTS strategy itself. When TB patients are brought closely and re-
peatedly together for diagnosis and administration of anti-TB drugs, they are exposed 
to cross- and super-infections from other TB patents. That this is a hazardous routine 
is also understandable from the fact that these patients share a number of risk factors 
and it has recently been shown that cross- and super-infections indeed occur [49, 127]. 
In South Africa Warren et al. found that 57% of patients infected with a BL strain were 
also infected with a non-BL strain. These results suggest that multiple infections and 
reinfections are frequent in South Africa, and that the initial infection does not induce 
an efficient protective immunity [49]. Strains that already have acquired drug resist-
ance will be increasingly selected and cross-infections may become an additional 
problem to the lack of compliance that may cause relapse and treatment failure. It is 
therefore of the utmost importance to introduce evidence based treatment at geo-
graphic and national level, and to develop a rapid test for RMP resistance to be per-
formed at the first encounter between the patient and the specialized TB services to 
prevent amplification of the MDR problem within health institutions [127].  
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1.6 EPIDEMIOLOGY AND RISK FACTORS FOR TB 
1.6.1 Epidemiology of TB 
During the 20th century a steady decrease in TB incidence took place in the 
industrialised parts of the world. This started even before the introduction of mass 
BCG immunisation, anti-TB chemotherapy, and active screening programs based on 
TST and Chest X-ray. The decline was strongly associated with improved socio-
economic conditions, better nutrition and enhanced housing conditions. It is assumed 
that more indoor space directly decreased the possibilities for transmission. Other fac-
tors such as pasteurization of milk, improved health services and understanding of 
communicable diseases, introduction of diagnostic tests and use of sanatoriums may 
also have contributed [128]. In the 1980s, however, the incidence of TB in these areas 
increased again. At the same time a doubling or tripling of notified TB cases was also 
seen in developing countries. In the industrialized countries factors as immigration 
from high-burden countries, the HIV epidemic and later in the 1990s the breakdown of 
the health infrastructure in the former communist countries have been pointed out as 
contributing factors [8]. For the high-burden countries increasing life expectancy, 
 
Estimated TB incidence rates, by country, 2006 
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population density, urbanization and extreme poverty as well as the rapidly spreading 
HIV epidemic and incomplete TB control programs apparently contribute to the in-
creasing prevalence of TB [104].  
Any factor that will prolong the period of infectivity of the TB patients will in-
crease transmission rates of M. tuberculosis. From an epidemiological point of view, 
no treatment is favourable to an unsuccessful treatment where DR or MDR is ac-
quired. As a result, the DOTS strategy emphasises on treatment outcome rather than 
on case detection. Enarson points at two factors that he considers responsible for an 
unsatisfactory outcome of treatment in a well-structured TB program. The first is diag-
nostic delay and poor adherence to the prescribed treatment regimen. The second is 
resistance to the medications used in the treatment [129]. These factors are discussed 
elsewhere in this thesis.  
As mentioned previously, it may be that current successful strains represent 
an important “driving force” behind the current pandemic. In North-West Russia, 
Toungoussova et al. found that the above mentioned “classical” reasons for increased 
transmission could not explain the rising epidemic, whereas a rapid spread of MDR 
strains of the BL seemed to be the most likely explanation [8].  
The next paragraphs outline the architecture of lineages of M. tuberculosis 
that have been described by molecular epidemiology. 
 
1.6.2 Lineages of Mycobacterium tuberculosis 
Utilizing Spoligotyping Sola et al. found 259 shared types among 3,319 iso-
lates from 47 countries, and six major clades of tubercle bacilli [130]. Filliol et al. found 
nine superfamilies of strains: M. africanum, Beijing, M. bovis, East African-Indian (EAI), 
Central Asian (CAS), T group of families, Haarlem, X family, and Latin American-
Mediterranean (LAM) family [131] (see also the chapter on TB evolution and aetiology 
above). The SpolDB4 presented by Brudey et al. defines 62 genetic lineages/sub lin-
eages, also called clades/subclades (a clade consists of all descendants of a common 
ancestor strain) [11].   
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 1.6.2.1 The East African-Indian lineage 
This lineage is characterized by a group of strains carrying a low number of 
IS6110 copies and another group with high numbers of IS6110.  EAI is frequent in 
South East Asia, India, and East Africa. It has been speculated that this lineage may 
have originated in Asia, where TB could have historically found favorable spreading 
conditions [132, 133]. Within the EAI lineage, new prototypic spoligotyping-signatures 
for 4 sub lineages were presented by Brudey et al. The EAI2 clade, previously named 
the "Manila family”, was merged with a group of strains from Thailand. EAI3 and EAI4, 
were phylogeographically specific from India and Vietnam respectively, with suggested 
designations of EAI3-IND and EAI4-VNM. Two lineages from Bangladesh were desig-
nated as EAI6-Bangladesh/1 and EAI7-Bangladesh/2. EAI6-Bangladesh/1 harbours 
specificity for the eastern part of the South Asian region since it was also found in 
neighbouring Myanmar. 
 
1.6.2.2 The Beijing lineage 
In brief, Beijing and Beijing-like strains represent about 50% of the strains in 
some studies from Far East Asia and 13% of isolates globally [134]. It must be em-
phasized that these studies are largely performed in major cities and may not be rep-
resentative for rural areas. The Beijing genotype belongs to the genetic group 1 of 
Sreevatsan, and has a specific spoligotype signature defined by Kremer et al. as ab-
sence of spacer 1-34, presence of at least three of spacers 35-43 and insertion of 
IS6110 in the genomic dnaA-dnaN locus [58]. In the Beijing region of China, this par-
ticular genotype was found in >80% of the TB patients and was thus called the Beijing 
genotype [7]. It has been speculated that the BL is a group of variant clones that ev-
olved from a common precursor maybe during the Genghis Khan reign or before [135]. 
It should be emphasized that the BL is a highly diverse group of strains and that the 
virulence of various isolates vary widely.  
The variable number tandem-repeat (VNTR) typing system (see 1.3.3.2) is 
currently being utilized to define sub-groups within the BL, particularly the MIRU 26, 
VNTR 1982, and VNTR 3232 loci seem to have a high discrimination power [136].  A 
study in North West Russia found 96% of BL strains to be "W strain/typical", while 4% 
were classified as "atypical", because they were more distant from the rest. Typical 
and atypical Beijing strains may be discriminated on the basis of specific IS6110 inser-
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tion sites [6]. The typical strains are likely to be of monophyletic origin and their dis-
semination has started recently. The atypical BL strains are evolutionary “older”; they 
probably have a common ancestor with typical BL strains [137].  
 
1.6.2.3 The Central Asian (CAS) family 
Utilizing IS6110 RFLP and spoligotyping the presence of a specific lineage 
that has been named the Central Asian (CAS) lineage has been reported from the In-
dian sub-continent [4, 131], Sudan, other sub-Saharan countries and Pakistan [11]. By 
IS6110 RFLP the CAS lineage shows a band pair in the high molecular weight region 
(12.1 and 10.1 kilobase pairs) in addition to multiple other copies. The characteristic 
spoligotype signature is represented by the absence of spacers 4-27 and 23-34 [11]. 
Brudey et al. demonstrated 22 lineages/sub lineages of M. tuberculosis. They split the 
CAS lineage into CAS1-Dehli type and CAS1-Kilimanjaro [11]. Later other sublineages 
of CAS have been described [138]. It has been demonstrated that the CAS family has 
been particularly successful in East Africa. The low diversity of the highly prevalent 
CAS family in Tanzania indicates that this family is spreading rapidly or reflects a 
slower evolution of the DR region which could possibly be a result of the missing 
spacers in the central part of the spoligopatterns of these strains. The CAS- and EAI-
families which were found to be abundant in Tanzania have previously been identified 
to have the most ancestral roots [40]. The absence of the Beijing family in East Africa 
indicates that it is unlikely that import of strains from Asia had a major impact on the M. 
tuberculosis population in Tanzania. This suggests an African origin of CAS and 
possibly of M. tuberculosis in general.  
 
1.6.2.4 The Haarlem family 
The Haarlem family was first described in the Netherlands by Kremer et al. [5]. 
It is characterized in spoligotyping by the absence of spacers 29–31 and 33–36. With 
IS6110 RFLP  these strains have a double band at 1.4 kb [139]. Within the Haarlem 
lineage, 4 sub lineages have been described. It has been suggested that Haarlem-4 
strains represent an intermediate genetic link between the Haarlem-1 and Haarlem-3 
genotypes [11]. More than 60% of the detected Haarlem strains have been localized in 
Armenia, Austria, Finland, Georgia, Iran, and Russia. The Haarlem family is also 
highly prevalent in Northern Europe, and to a lesser extent in the Caribbean. It is also 
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found in Central Africa and Saudi-Arabia, possibly introduced by European coloniza-
tion and migratory activities [140]. 
 
1.6.2.5 The Latin American and Mediterranean (LAM) family 
.The LAM family was originally defined by the absence of spacers 21-24 in the 
spoligotyping and the presence of an exact tandem repeat (A) allele equal to spacer 2 
[130]. The diversity within the group is substantial, and according to the SpolDB4 12 
subtypes have been defined [11]. Within the LAM lineage, the LAM7 sub lineage was 
renamed LAM7-Turkey. Similarly, the LAM10 sub lineage was renamed as LAM10-
Cameroun. Recently, two new sub lineages have also been presented; LAM11-ZWE 
and LAM12-Madrid1. The LAM clade is frequent in Mediterranean countries and in 
Latin America, but is increasingly found also in Africa and other countries. LAM is well-
known for the XDR-TB outbreak in South-Africa [141], that killed 52/53 patients and 
received intense international attention.  Paleopathological data support the pre-
existence of TB before the arrival of the Spanish conquistadors; it may have been en-
demic in Latin America or Africa or both, later spreading to Europe. But the LAM 
strains might as well have been introduced by the Europeans [142]. 
 
1.6.2.6 The X family 
The X family (X1-X3 sub lineages) of strains is defined by a low number of 
IS6110 copies and the absence of spacer 18 in the spoligotyping [143]. This genotype 
is today a well-characterized family. It is prevalent in UK, in USA and in former British 
colonies. The CDC1551 strain belongs to the X family, which was once suggested to 
be highly virulent. The X family seems to be linked to Anglo-Saxon countries. It was 
the first group identified in Guadeloupe and French Polynesia and is also present in 
South Africa, the Caribbean, Mexico and India [131]. 
 
1.6.2.7 The T family 
The "T" family still remains ill-defined with more than 600 unclassified spoli-
gopatterns. They were stratified into 5 subclades (T1-T5) based on single-spacer dif-
ferences by Brudey et al. [11].  The T family belongs to the PGG 2 and 3, are loosely 
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defined by the absence of spacers 33-36 in spoligotyping, and have been grouped 
together because they are difficult to link to other families [40].  If intact polyketide syn-
thase genes are present, they appear to be more virulent than other strains [144]. A 
total of 8 nested clades, with robust spoligotyping-signatures were extracted from the 
5 sub-clades.  With the exception of "Tuscany", their names indicate their proximate 
upper-clade designation (T1 to T5), followed by their presumed geographical specific-
ity: T3-Ethiopia, T5-Russia/1, T1-Russia/2, T3-Osaka, T5-Madrid/2, T4-Central Eu-
rope/1, T2-Uganda, and "Tuscany". The strain that caused the large outbreak of drug 
resistant TB in Stockholm in the years 2003-2005 ws also assigned to this lineage 
[118]. 
 
1.7 THE POOL OF INFECTION 
1.7.1 Diagnostic Delay is a key variable to monitor the pool of infectious 
TB at a local level 
 
A goal of TB control programs is to prevent transmission within the community. 
Achieving this goal takes considerable time, because most individuals in endemic are-
as are already infected, constituting a reservoir that continuously contributes to the 
pool of infectious cases. An effective TB control program requires early diagnosis and 
immediate initiation of treatment. Delay in diagnosis is important for disease prognosis 
Pool of infectious TB 
Self -cure 
Detected and 
treated 
Death 
Recent or remote 
infection 
The Dye model of the infectious pool [3] 
 45 
at the individual level, transmission within the community and the reproductive rate of 
the TB epidemic [3, 145]. Most transmissions occur between the appearance of cough 
and initiation of treatment. Madebo et al. found that patients become more contagious 
as the delay progresses; the longest delays are associated with the highest bacillary 
numbers on sputum smears [146].  
The main indicator used by the WHO is the case detection rate (CDR), which 
is defined as the notification rate of new cases of smear-positive (ss+) TB divided by 
the estimated incidence rate. The WHO has defined a CDR of 70% as a target under 
the Millennium Development Goals [147]. CDRs are calculated based on tuberculin 
surveys, but these surveys require resources and expertise that is often unavailable. 
An alternative and more feasible approach could be to use data that can be obtained 
from local TB programs’ records, eliminating the need for additional resources.  
Among the possible variables that could be utilized to monitor the pool of in-
fectious TB in a population is diagnostic delay (DD). Several models have been devel-
oped to describe the infectious pool, and one of the most comprehensive is the dy-
namic model of Dye et al. (above figure). Individuals enter into the pool when they de-
velop active pulmonary TB and become infectious at a certain rate, and leave the pool 
as they start treatment, self-cure or die at certain rates. The size of the pool, and 
hence the burden of contagious cases, is defined by the relative size of these rates 
[148]. Each patient’s contribution to the infectious pool is equal to the number of days 
that he or she remains infectious, that is, the interval between the onset of symptoms 
and two weeks after the patient starts treatment, when he experiences self-cure, or 
dies. There is convincing evidence that a large majority of TB patients are able to re-
call the onset of symptoms with acceptable accuracy [149]. In our study we intended 
to perform a systematic recording of the diagnostic delay for all categories; new pul-
monary TB cases, retreatment cases, failures and undiagnosed cases, and hence ob-
tain an estimate of the total infectious pool. Of these four categories, new sputum 
spear-positive TB cases contributed the greatest number of infectious days. We hy-
pothesized that a local TB program could use a systematic recording of diagnostic de-
lay as a quantifiable variable to monitor the infectious pool (PAPERS III, IV). 
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1.8 THE NEED FOR NEW DIAGNOSTIC TESTS 
1.8.1 High endemic areas: an urgent need for a feasible, inexpensive 
and highly sensitive screening test that discriminates active from la-
tent TB 
The diagnosis of active pulmonary TB in high endemic countries is primarily 
based on microscopy of sputum-smears, which are neither sufficiently simple, rapid 
nor sensitive to serve as a feasible screening test. Sensitivity is low, because more 
than 104 bacilli per ml of sputum are required for detection, and approximately 50% of 
the active pulmonary TB is smear negative [117]. Lack of efficient diagnostic tests for 
sputum-smear negative (ss-) TB is among the major challenges combating the world-
wide increasing TB epidemic.  
Globally, there were an estimated 709 000 new HIV-positive TB cases in 2006 
[111], and TB is killing 1 out of 3 subjects who die with AIDS [150]. In HIV-infected in-
dividuals delayed diagnosis of TB for more than three weeks after onset of active pul-
monary TB is associated with 45-85% of the deaths [151]. More than 50% of the HIV 
cases with TB have a negative sputum-smear test [152].   
More than 95% of patients with chronic cough do not have TB, and early con-
tact with health services causes delay rather than suspicion of TB [153]. In Mumbai, a 
typical high endemic urban area,  80% of healthy individuals were found to be latently 
infected with TB [154]. The major task of a new screening test is therefore to differ-
entiate active pulmonary TB from latent infection and previous BCG vaccination. This 
because the strategy should be to refer the individuals who come out as positive with 
the screening test to the National TB Program for further investigation with sputum 
microscopy and a clinical follow up system. The tests do not need to have a particular 
high specificity, but the sensitivity needs to be as close to 100% as possible. 
Molecular techniques such as genome sequencing, cloning and expression, 
and purification of proteins have identified novel antigens for serodiagnosis of TB. 
ELISA-based serological tests utilizing a range of different antigens have been intro-
duced, unfortunately all with low sensitivity and specificity [155]. This is mainly be-
cause of the heterogeneity of the antibody response in TB patients from different geo-
graphical locations. Antigen recognition in infected individuals is also highly hetero-
geneous due to factors such as stage of disease, strain of the bacilli, bacillary load, 
difference in human lymphocyte antigens (HLA) types and competence of the immune 
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system. In addition, in the human host there is a substantial cross-reactivity between 
M. tuberculosis and environmental mycobacteria, BCG and other bacteria such as e.g. 
Nocardia asteroides and Corynebacterium pyogenes [156]. This implicates that the 
antibody specificity is depending on the microbiological environment the individual has 
been exposed to before she is exposed to M. tuberculosis [157]. 
Due to advances in molecular biological techniques, an increasing number of 
novel antigens are being identified. The most promising antigens have been fusion 
proteins like CFP-10, M. tuberculosis 8, M. tuberculosis 48, M. tuberculosis 81 and the 
38-kDa protein, which show encouraging results in detecting antibodies in sera of pa-
tients, also in sera of those with TB-HIV co-infection. 
In a review of M. tuberculosis antigens with serodiagnostic potential Abebe et 
al. divided the candidates into six categories based on the type of TB they preferen-
tially detect [155]: 
 
1. Antigens that can be used to detect latently infected patients or household contacts: 
16-kDa (a-crystallin), 14-kDa and 6-kDa antigens. 
2. Antigens that can be used to detect TB patients at an early stage of disease:          
M. tuberculosis 81, MPT51, MPT32 and Ag85C. 
3. Antigens that can be used to detect TB patients co-infected with HIV:                   
TB9.7, TB15.3, TB16.3, TB51, M. tuberculosis 81, MPT32 and Ag85B. 
4.  Antigens that can be used to detect antibodies in sera of patients with extrapulmo-
nary TB:  
DAT, TAT, SL-I, cord factor, GST-822, ESAT-6, M. tuberculosis 11 (CFP-10), TB9.7, 
TB15.3, TB16.3, TB51 and 38-kDa antigen. IgA antibodies to MPT64 have been stud-
ied in pleural effusions. MPT64 is also readily detected in tissues of TB patients using 
immunohistochemistry. 
5. Antigens that can be used to detect patients with active pulmonary TB:  
ESAT-6, M. tuberculosis 11 (10-kDa), 19-kDa, 14-kDa, 16-kDa, MPT64, M. tuberculo-
sis 48, M. tuberculosis 81 (88-kDa), MPT51 (27-kDa), A-60, TB9.7 (10-kDa), TB15.3 
(15-kDa), TB16.3 (16-kDa) and TB51 (51-kDa). 
6. A combination of recombinant proteins and a fusion polyprotein which may detect 
different forms of TB (caused by different strains and in different host populations):  
the 38-kDa antigen, M. tuberculosis 8, M. tuberculosis 11, M. tuberculosis 48, M. tu-
berculosis 81, DPEP, TB9.7 and TB16.3. 
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A particularly interesting study conducted by Mukherjee et al. in Calcutta fo-
cuses on peptides encoded by the RD1 region Rv3872.  The immunological reactivity 
against a mixture of two peptides (P8 and P9) encompassing amino-acids 57–84 cor-
related well with that obtained using full-length Rv3872. They showed the highest level 
of antibody response in comparison with other peptides. Most interestingly Mukher-
jee’s research showed that a mixture of P8 and P9 was able to discriminate between 
pulmonary TB patients and healthy BCG-vaccinated individuals [158].    
 
1.8.2 Low endemic areas: The need for effective screening tools that 
can be directed towards risk groups 
TB used to be among the most serious public health threats in Norway. Dur-
ing the last fifty years this has changed radically, as the new case detection has de-
creased to only 294 cases in a population of 4.5 million in 2007, out of which approxi-
mately 80% where born outside Norway. New immigration, increasing internationaliza-
tion and reactivation can change this situation although the control program in Norway 
can still handle the challenge of imported TB [117]. In a recent 12-year study, importa-
tion of M. tuberculosis was shown to lead to increased incidence of TB but otherwise  it 
had little effect on the TB situation in Norway. The social situation of the immigrant 
population was expected to have changed during this 12-year period. These changes 
were in part used to explain the changing TB epidemiology, but the low number of 
clustered strains could not support the statement that public health was hampered by 
immigration from high-incidence countries [117].  
To prevent a resurge of M. tuberculosis in Norway the Government has given 
TB a high priority. One of the results is the new law on TB control, where screening of 
risk groups as immigrants and health personnel as well as obligatory DOT and effec-
tive contact tracing are key issues [159].  
Compulsory screening for TB in the form of chest X-ray and tuberculin skin 
tests (TST) on entry has been implemented in Norway since the mid-1970s for indi-
viduals from high TB prevalence countries who intended to stay more than three 
months [159]. In a retrospective cohort study of 19912 asylum seekers with a mean 
follow-up of 6.3 years 76 persons were diagnosed with TB, of whom 43 (57%) had 
pulmonary TB. Twenty-two cases were found through screening at entry. Eleven per-
sons had abnormal mass miniature X-rays, but had inadequate follow-up and were 
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diagnosed later through passive case finding. Mass miniature X-ray itself had a sensi-
tivity of 96% and a specificity of 98% for pulmonary TB, diagnosed within 1 year after 
arrival [160]. 
Delay in start of TB treatment causes patients to have more advanced dis-
ease, more complications, higher mortality and more TB transmissions from each case 
[161]. Styblo calculated that a patient with untreated ss+ pulmonary TB may infect on 
average more than 10 patients annually and over 20 during the natural course of un-
treated disease until death [101].   
Diagnosing latent TB has been based on TST. This test has many disadvan-
tages, but has been used due to the lack of better alternatives. The main problem of 
the TST is the low specificity [162]. Both BCG immunization and exposure to envi-
ronmental mycobacteria can result in a false positive TST. In addition, 15%-25% of 
those with active TB have a negative TST [163]. The sensitivity of the TST is easier to 
define than their specificity in surveys. Given a normal distribution, the number of in-
fected individuals missed because they have an induration less than the cut-off value 
can be calculated. For culture confirmed TB there are diverging reports of sensitivity 
from 100 % (McConkey et al. [164]), 89 % (Britton et al. [72]), 69 % (Lalvani et al. 
[165]) to 63 % (Liebeschuetz et al. [166]). 
Among the risk groups we targeted health care workers (HCW) at Norwegian 
hospitals (Paper V). The current policy is to perform environmental screenings after 
cases of unprotected exposure to ss+ pulmonary TB if a case of not priory known pul-
monary TB was admitted, and no isolation or preventive measures were established. 
In concordance with the national guidelines super-infection is defined as an increase 
in TST induration from the last previous TST of 	 10 mm or a TST of 	 15 mm if previ-
ous TST status is unknown [159]. The individuals defined as super-infected are fol-
lowed up with consultations at the pulmonary outpatient department and annual chest 
x-rays for three years.  
However, recently developed in vitro assays based on T cell production of 
INF- in response to the M. tuberculosis specific antigens ESAT-6 and CFP10 have 
contributed to improved specificity in TB screening. These RD1 encoded protein anti-
gens are absent in all vaccine strains of M. bovis BCG and most non-tuberculous my-
cobacteria (except M. marinum, M. szulgai, and M. kansasii), and such tests can 
therefore distinguish M. tuberculosis infection from infections caused by other myco-
bacteria or previous BCG-vaccination [165, 167]. Two commercially available and 
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regulatory agency approved (EU, Quantiferon-TB Gold (QFT) (Cellestis) also by FDA). 
Two test systems can be used: T-SPOT.TB (Oxford Immunotec) is an ELISPOT assay 
based on analysis of a defined number of isolated blood cells, whereas QFT is a 
whole blood ELISA based test. The tests have comparable specificity (98-99 %), but 
sensitivity is reported to be somewhat higher for the T-SPOT.TB test (97 %) as com-
pared to QFT (90 %). This difference is most pronounced in immuno-suppressed per-
sons and in children, where the frequency of indeterminate results is demonstrated to 
be higher for the QFT test [168, 169].  
With their high specificity, IFN- release assays have the potential to improve 
both the diagnosis of TB in infected individuals as well as the utilisation of public 
health resources for TB control. The tests are not suitable for high endemic areas be-
cause they are not able to differentiate between latent infection and active disease, 
and they are too resource demanding for poor countries. In paper V we compared the 
T-SPOT.TB test with TST in TB exposed hospital personnel and used the results to 
assess the role of IFN- release assays for improved screening of this target group as 
well as the rate of TB transmission during short-time exposure in a low TB endemic 
country. 
 
1.9 TO OVERCOME CULTURAL, SOCIOLOGICAL AND ECONOMICAL 
CONSTRAINTS TO AN EFFECTIVE TB CONTROL PROGRAM AT A 
LOCAL LEVEL. THE DECENTRALIZED BRAC MODEL AS AN EXAM-
PLE. 
A panel of Health Care Workers in KwaZulu-Natal defined stigma, denial, and 
lack of education as the primary reasons for failure to complete TB treatment. The re-
sults also highlighted inadequate support for and monitoring of the program as a result 
of a lack of administrative supervision, which is typical in many high-endemic countries 
with weak health care infrastructures [170]. A similar qualitative study from Swaziland 
raised two main societal issues, which had major impact on the success of the TB 
program: health beliefs and poverty. It is seen that health beliefs can have a major 
impact on treatment-seeking behaviour and outcomes of TB treatment. Problems re-
lated to poverty were of two main types: insufficient funds to attend for review, and 
lack of food whilst on TB treatment [171]. There is no doubt that TB in many aspects is 
“the poor man’s disease”. In Brazil a recent study found the socioeconomic factors to 
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account for 87% of the total variation of the disease prevalence. The disease preva-
lence was clearly higher in the poorest areas [172].  
In our implementation of the field work in Bangladesh (Paper I, II), we co-
operated with Bangladesh Rural Advancement Committee (BRAC), the largest NGO in 
the world, employing approx. 100 000 people. The twin objectives of BRAC are pov-
erty alleviation and empowerment of the poor, and to provide and protect livelihoods of 
around 100 million people in Bangladesh. The organisation implements programs on 
poverty alleviation through micro financing, non-formal primary education, women’s 
health measures, and disease control [173]. 
BRAC has been implementing a TB program in Bangladesh with DOTS since 
1984, well before the DOTS strategy was launched by WHO in 1997. Since the im-
plementation of DOTS, consistent success rates of around 85% have been reported. 
In the BRAC program, the responsible community health worker (CHW), the so called 
Shaisto Shebika, comes from the village in which she works, and thus knowledge 
about the family situation and culturally appropriate interaction with patients is ensured.  
The TB-control program, which is implemented in collaboration with the Gov-
ernment of Bangladesh (GoB), has gradually been scaled up to cover a population of 
83 million [173]. At the core of the program is the Shaisto Shebika, the CHW, who is a 
member of the local village organisation and supported by BRAC through micro-
financing and other development inputs. CHWs are all women, mostly unschooled, 
who receive training from BRAC on the treatment of common illnesses including TB. 
The CHW identifies people with chronic cough and sends samples of sputa to a local 
BRAC laboratory for microscopy. The ss+ cases are brought to treatment immediately. 
The CHW provides the drugs, which are received free from the GoB. During the initial 
2 months after identification, the patients come to the CHW’s home daily for drugs. For 
the remaining period of treatment, the patients are given a week’s supply at a time. 
Before the CHWs initiate the treatment, the patient has to deposit a sum of money and 
sign a bond that she or he will complete the treatment; in case of default, the bond 
money is forfeited. The factors responsible for success include the learning culture of 
the BRAC organisation, involvement of CHWs, the bond money requirement, program 
out-reach, provision of free drugs, good management, and availability of technical and 
financial resources.   
A second issue raised by the Bangladesh experience is the need to demystify 
TB treatment. The success of the CHW approach challenges the myth that physicians 
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are essential at all stages of TB treatment. Trained local women with good supervision 
can accomplish seeming miracles in the villages of developing countries. The more TB 
treatment is brought outside hospital walls and the dependence of experts, the greater 
the success of DOTS; the example of oral rehydration therapy in many developing 
countries including Bangladesh bears testimony of this.   
 
1.10 TB IN BANGLADESH 
Bangladesh has the sixth highest burden of TB cases among all nations. For 
2006 it was estimated that there were 300,000 new cases, out of which 137,000 were 
infectious, ss+ cases. The annual incidence of TB was 101 per 100,000 population for 
ss+ cases and 225 per 100,000 for all forms. It was estimated that TB caused 70,000 
deaths. The official case detection rate was as low as 41%, but due to a substantial 
private health sector and that TB drugs are available on the open marked the correct 
CDR is difficult to estimate. The success rate of detected cases under DOTS was 84%. 
With an estimate of 300,000 new cases annually, those cured under the NTP com-
prised only 3.2% of all new cases in 2003 [104].  
A TB service delivery survey performed in 2004 found multiple reasons be-
hind the low case detection rates. First, too few diagnostic centres where sputum mi-
croscopy is performed. One microscopy centre per 100,000 population is recom-
mended in high-burden countries, but a 2004 WHO investigation indicated that in 
Bangladesh each Upazilla (sub-districts of approximately 300,000) is served by only 
one centre with a sputum microscopy facility. Second, only about half the population 
had real access to DOTS services. In most urban areas, the district hospitals, aca-
demic institutions, private clinics, and institutions like prisons and corporate hospitals 
had not implemented DOTS. About 70% of the microscopy centres in the DOTS pro-
gram delivered substandard services, both due to poor training and availability of re-
freshment courses and follow up of the laboratory technicians [174]. An estimated 60–
70% of TB patients in urban areas seek care from the private sector. No records of 
patient numbers or treatment patterns are maintained within this service. The NTP as-
sume that just over half of all patients seek care from chest specialists, health centres, 
and NGO clinics. Most of these providers do not offer DOTS supported treatment, al-
though some of the NGOs have implemented DOTS [175]. 
Several other factors are also believed to contribute to Bangladesh’s TB bur-
den. After introducing DOTS in the NTP, there has been concern about the availability 
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of anti-TB drugs for the poorest patients has been compromised. First, it requires re-
courses to go to the clinic on a daily basis, resulting in a lack of income. Second, lack 
of education makes it also difficult for the poor to achieve the knowledge and under-
standing they need to be motivated for the completion of treatment. A study performed 
in 1991 in the rural area of Chagalnaya found an increasing prevalence with increas-
ing age, a higher prevalence among males and among occupation groups like farmers, 
workers and housewives. In addition, TB was more prevalent among illiterates and 
those living in overcrowded, low standard houses. They also found that 85.7% of the 
detected ss+ infectious cases were formerly undetected and untreated [176]. Other 
studies have also detected high incidences in densely populated urban areas with 
poor living conditions [177]. Seventy-nine percent of new infectious TB cases are 
found in the economically active age groups (15-54) [177].  Gender also seems to be 
important; there are twice as many new ss+ cases registered for treatment among 
men than among women. A prevalence study confirmed the higher prevalence among 
men was real, and not due to female cultural constraints to achieve treatment [178]. 
 
1.10.1 TB treatment in Bangladesh 
The Bangladesh NTP was officially established in 1993 through endorsement 
of the DOTS strategy for TB control (World Health Assembly, Geneva, May 1991). The 
NTP now covers 99% of Bangladesh’s geographical area. Under the NTP, DOTS ser-
vices are delivered from more than 500 Government-run centres and NGO clinics in all 
upazillas, districts, and city corporations [179]. There are two types of GoB facilities: 
Upazilla health complexes (UHCs): There are 460 UHCs, each covering an 
average population of 270,000–300,000; UHCs are 31-bed hospitals with indoor facili-
ties and field functionaries to deliver primary healthcare (PHC) services to the rural 
populations. UHCs are comprehensive sub-district level facilities that provide TB care 
along with a wide range of other preventive and curative services, including both in- 
and out-patient care. 
Chest disease clinics (CDCs): The 45 CDCs are secondary-level care facili-
ties in 44 district headquarters; they serve large and widely variating populations. They 
are devoted specifically to the screening, diagnosis, and treatment of TB patients. 
They serve as DOTS centres and support the NTP through diagnosis of pulmonary TB 
cases, proper referral of patients for treatment to respective UHCs, and provision of 
technical advice according to national guidelines. They refer complicated cases to ter-
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tiary-level hospitals. There are also 11 major NGOs (with sub-awardees), including 
BRAC, that provide DOTS under the NTP umbrella. The NGO Service Delivery Pro-
gram (NSDP) is one of them and is responsible for providing DOTS in the major urban 
areas, i.e. the city corporations. This is implemented through NGO clinics under the 
NSDP network. Not all NGO clinics in Bangladesh participate in the network of the 
NSDP. Although NSDP has both urban and rural NGO clinics, only some of the NGO 
clinics located in the city corporation areas provide DOTS support, in terms of diagno-
sis and care. Acid-fast bacilli microscopy is provided free in all DOTS centers, while 
chest X-ray is used for the diagnosis of smear-negative or complicated cases, mainly 
in the CDCs. TB-DOTS treatment is provided free from all centers and, as much as 
possible, decentralized at the community level through community health workers, vil-
lage doctors, the GoB, and NGO staff [179]. 
 
1.10.2 Drug resistance in Bangladesh 
The national drug resistance testing (DTS) facility operated by the NTP was 
discontinued in 1995. The 1996 WHO Report states that before the introduction of the 
NTP, and DOTS in 1993, up to 60% of the TB cases in Bangladesh were treated by 
private clinicians. Monotherapy and other inadequate treatment regimens were com-
mon, and anti TB drugs were available on the open market [180]. Since the early 
1990s DOTS has gradually expanded to cover all regions of Bangladesh, but in 2003 
the CDR of sputum ss+ cases was still only 33 %, compared to the WHO goal of 
above 70% [181]. In 1995 a baseline study at the start of the NTP was performed by 
sampling of pre-treatment sputum from all newly registered ss+ cases in the Greater 
Mymensingh District. In this mainly rural population resistance among new cases to 
INH was 5,4%, to RMP 0,5%. Resistance to INH and RMP in previously treated cases 
were 25,9% and 7,4% respectively. MDR-TB was observed in one new case (0,23%) 
and in 5,6% of previously treated patients. It was concluded that NTP regimens for 
new and retreatment smear positive cases are appropriate, the more so since HIV was 
virtually absent. Indications for the retreatment regimen should be extended to involve 
all patients who had any previous treatment for at least one month. The prevalence of 
drug resistance was found to be low, but may be expected to rise with improved eco-
nomical conditions if the private distribution of TB drugs cannot be avoided [182]. 
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Another study from 2000 in an urban TB clinic in Dhaka showed resistance in 
29,7% of new patients to at least one drug; 15,8% to INH, 10,9% to RMP, 6,9% to SM, 
2,9% to EMB and 3,9% to PZA. MDR-TB was found in 4,95% of the cases. Ciproflox-
acin was tested against 30 strains of M. tuberculosis, 67% of which were resistant 
[183].  
In Matlab, a rural area, also studied after the introduction of DOTS, MDR-TB 
was absent among new cases, while it was common (27.3%) among previously 
treated cases [184]. Studies from rural India (1997-2003) have demonstrated that re-
sistance to RMP in new cases was 0.5-4.4%  and that the prevalence of MDR-TB was 
0.5-3% [185].  In conclusion TB drug resistance seems to be higher among new pa-
tients in urban areas than in rural areas, and substantially higher in previously treated 
cases than in new cases, both rural and urban areas. The same range of frequencies 
of MDR-TB among new cases were described in Myanmar (4.2%) [186], Thailand 
(4.2%) [187] and China (4.5%) [188].  
Questions that need to be answered are: Why is the prevalence of TB in Ban-
gladesh one of the highest in the world and why is it increasing? The prevalence of TB 
in Chagalnaya in 1991 was significantly higher than the rates found in the TB Survey 
of Bangladesh 1964-66 [189] and in the Epidemiological study of 1984 [190]. Seventy-
nine percent  of new infectious TB cases are found in the economically active age 
groups (15-54) [177]. Therefore, TB is not only a major killer but also a heavy eco-
nomic burden on one of the poorest countries in the world. A major question arises: 
What kind of strains are contributing to the TB epidemic in Bangladesh? Do we face a 
situation of increasing dominance of particular emerging successful strains?  
 
1.11 STUDIES OF MOLECULAR EPIDEMIOLOGY OF                          
M. TUBERCULOSIS IN BANGLADESH  
The information on the molecular epidemiology of M. tuberculosis strains in 
Bangladesh is limited. A study performed in 1999 included 48 strains from a hospital in 
Dhaka city. A total of 34 strains (71%) were grouped by spoligotyping into nine differ-
ent clusters; the largest comprised 15 (32%) isolates of the BL, whereas the remaining 
eight clusters consisted of two to five isolates [4]. This material indicated that BL play a 
major role, but needed confirmation, especially by materials from rural areas like Su-
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namganj. Also the study from patients in one hospital in Dhaka could represent an co-
incidental outbreak, thus confirmation and expansion of population size was called for. 
A study utilizing spoligotyping of non-hospitalized TB patients of both urban 
(Dhaka) and rural (Matlab) areas of Bangladesh were performed in 2001-2003 by 
Rahim et al. Spoligotype patterns were compared with the SpolDB4 database. A total 
of 193 of 224 (86%) isolates were clustered into 31 shared types (ST) of 2 to 34 
strains, whereas 31 strains (14.0%) were unique. After matching with the SpolDB4 
database the strains were clustered into four major clades: 75% percent of all strains 
belonged to the principal genetic group 1 (PGG 1) [191] that includes BL, EAI and 
CAS and 25.0% belonged to PGG 2 and 3. 
EAI was the most prevalent clade and constituted 44% of the isolates. Most 
strains of the EAI clade could be classified into EAI1 to EAI5. Within the EAI clade, 49 
strains had the spoligotype signature designated EAI6-Bangladesh1 (EAI6-BGD1). 
Other EAI subclades such as EAI4 (Vietnam) and EAI8 (Madagascar) were not found. 
The fact that  “ancestral” TB clades [40] like the EAI are predominant in Bangladesh 
makes it likely that there has been a historical presence of endemic strains. Rahim 
argues that the emergence of an endemic new lineage (EAI6-BGD1) is also evident 
from the comparison with results from an unpublished study by Rigouts et al. (personal 
communication to Rahim). The EAI6-BGD1 lineage’s origin in Asia is not yet precisely 
dated, but these strains belong to PGG 1 (assessed by katG-gyrA polymorphism [42]). 
On the other hand: a recent study documented a single nucleotide polymorphism lo-
cated within the nitrate reductase (narGHJ) operon promoter clustering BL together 
with PGG 2 and 3 organisms [192]. The CAS family constituted 15.0% of the isolates 
in the study by Rahim et al. [191]. The predominant Prototype ST 26 is known as the 
Delhi type and is prevalent in north India [193]. Other present CAS 1 prototypes in the 
Rahim study were ST 794, ST1120, ST 288 and the newly described ST2149 [191]. 
This family is prevalent in Pakistan, Sudan, and Libya. The CAS 2 variant ST 288 was 
also detected. Modern strains (PGG 2 and 3) constituted 25.0% of the strains. The 
Latin-American and Mediterranean (LAM) clade was the second most prevalent mod-
ern clade. The ST 137, one of the European low IS6110 copy clades, was also found 
[191]. It is related to T-PRT, known as the “Portuguese type” (ST 244) [11]. The Portu-
guese settled at the Indian subcontinent at the end of the nineteenth century, which 
confirmed the likely existence of a common ancestor of today’s clones.  
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1.12 TB IN ETHIOPIA 
TB is considered a major public health problem in Ethiopia, ranking as num-
ber seven just behind Bangladesh among the 22 TB high-burden countries [194]. In 
2006 the incidence of new ss+ TB cases was 168 per 100 000 pop. The incidence of 
all new cases was 379 per 100 000 pop. and the total prevalence of all cases was 643. 
The annual TB death rate was 84 per 100 000 pop, or approximately 70 000 in a 
population of 81 million people [111]. In 2000 the worldwide percentage of MDR-TB 
was calculated to be 3.2% of all new TB cases, in Ethiopia it was 2.3%.   
A study from Addis Abeba in 2004 found the incidence of MDR-TB in not pre-
viously treated TB cases to be 5,3%. They also found an increasing resistance to one 
ore more drugs from 14% in 1996 to 22% in 2001 [195].  
Before the introduction of DOTS in Ethiopia, 82% of TB patients were re-
ported to have failed to complete treatment [196], while defaulting after the introduc-
tion of DOTS has been reported as low as 11.3% [197]. In another study a significantly 
declining trend in treatment non-completion from 38% to 18% over six years during 
1994–2000 was reported. Patients interrupted treatment mainly because of long dis-
tances to the health facilities, poor awareness about the disease and treatment length, 
side effects and lack of family support [198]. In Addis Abeba a qualitative study con-
cluded that patients often discontinued treatment because of "social problems" and 
"feeling of improvement" [196].  
Our field study in Bangladesh did not obtain information on diagnostic delay. 
The Amhara Region of Ethiopia was chosen to demonstrate the usefulness of DD as a 
tool to monitor the infectious pool of TB in a population because Yimer et al. had al-
ready performed a study in this area on DD in new ss+ patients [199]. By revisiting the 
area additional information from the NTP protocols was obtained on ss- patients, re-
treatment- and defaulted cases. 
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1.13 NORWAY 
1.13.1 TB in Norway 
Norway has one of the lowest incidences of TB in the world. Dahle et al. 
surveyed all notified TB cases in Norway between 1994 to 2005, and identified a total 
of 135 clusters, indicating a high genetic diversity. From 1994 to 2005, Norwegian 
annual TB incidence increased 11%, from 5.6 to 6.2 cases per 100,000. By 2005, for-
eign-born individuals (7.9% of the population) accounted for 78% of Norwegian TB 
cases - versus 46% in 1994. This striking finding reflects declining case numbers 
among Norwegian-born persons, a near-doubling of the foreign-born population, and 
increased incidence within this group [117]. 
The great majority of the cases are due to reactivation of previously ac-
quired disease; the ethnic Norwegians are mostly elderly people who contracted the 
disease before 1960, and the foreign-born cases had a latent infection when arriving in 
Norway. Transmission between immigrants and native Norwegians is rare. Two major 
outbreaks have been identified; one mainly among immigrants and one among native 
Norwegians [200]. The fact that they had been going on for several years has also 
been described in other low endemic areas, indicating that even with a good national 
program for TB surveillance, outbreaks are difficult to identify mainly because TB is 
not suspected [201].  
The key elements in TB control are to cure the individual patient, interrupt 
transmission of TB to others and prevent the tubercle bacilli from becoming drug re-
sistant. Incomplete treatment may result in excretion of bacteria that may also acquire 
drug resistance and cause increased morbidity and mortality. Treatment outcome re-
sults serves as a tool to control the quality of TB treatment provided by the health care 
system.  
A study conducted by Farah et al. evaluated the treatment outcome for new 
cases of culture positive pulmonary TB in Norway during the period 1996-2002. 
Among the 655 patients included, the total treatment success rate was 83%. Three 
percent defaulted treatment, 9% died and 4% transferred out. The default rate was 
higher among foreign-born and male patients [202]. TB in Norway is also discussed in 
section 1.8.2. 
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1.13.2 Norwegian Health personnel as a risk group 
Several studies from the pre-fingerprinting era concluded that prolonged con-
tact with an infectious case of TB was the usual transmission pattern. The risk of being 
infected could be calculated as a function of the time spent sharing room air with the 
index case [203, 204]. When contact tracing utilizing fingerprinting methods as IS6110 
RFLP and Spoligotyping became available, it was revealed that a substantial propor-
tion of TB cases must have acquired TB  infection as a result of a casual contact [205, 
206].  
HCWs are constantly at risk of unprotected exposure and a better under-
standing of M. tuberculosis transmission after brief exposure is essential to improve 
the follow-up routines. As most new infections result in latent TB infection, strain 
fingerprinting is not an amenable tool to trace transmission.The current policy in Nor-
wegian health institutions is to perform environmental screenings based on TST after 
TB exposure.   
A major problem in many Norwegian hospitals is that the same HCWs have 
undergone multiple screenings. Some wards like pulmonary and infectious disease 
units even routinely screen their personnel with TST annually. The result is a massive 
boostering, and it is not uncommon that more than half of the staff of these kinds of 
wards is defined as TST positive. Thus, due to the low specificity and utilization  mal-
practices of the TST [167], a large proportion of the group defined as TST positive af-
ter exposure are probably false positives, which leads to incorrect treatment, waste of 
resources, and unnecessary anxiety. As discussed in section 1.8.2; two new blood 
tests, based on detection of INF- produced by T cells in response to antigens specific 
to M. tuberculosis and encoded by the RD1 region, have been found to be more accu-
rate than the TST. Our study of exposed HCW in Norway (Paper V) compared TST to 
T-SPOT.TB.  
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2. MATERIALS AND METHODS  
2.1 AIMS OF THE STUDIES 
This thesis aimed at contributing to the current knowledge that forms the fundament 
for local, national and international control of TB.  
SPECIFIC OBJECTIVES 
1. MOLECULAR EPIDEMIOLOGY 
a. To describe the main families of M. tuberculosis, and detect the degree of 
reactivation in a rural area of Bangladesh.  
b. To describe the drug susceptibility pattern in isolates from ss+ patients in 
rural parts of Bangladesh.  
c. To characterise demographic, social and medical risk factors contributing 
to the spread of TB in rural parts of Bangladesh.  
2. DIAGNOSTIC DELAY 
a. To evaluate if treatment delay can be utilized as key variable for monitor-
ing the pool of infectious TB in a high-incidence region. 
3. IDENTIFICATION OF RECENT INFECTION IN A LOW-ENDEMIC SETTING 
a. To determine the rate of M. tuberculosis infection after unprotected expo-
sure of personnel in Norwegian hospitals. 
b. To compare the efficacy of the T-SPOT.TB test with TST as tools to detect 
infection in TB exposed hospital personnel.  
c. In the light of costs and benefits both at the individual and national level to 
evaluate improved follow up strategies for TB exposed hospital personnel. 
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2.2. BANGLADESH 
2.2.1 Experimental design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All patients attending the BRAC TB Clinics of 
Sadar, Jagannathpur, Derai and Chattak Upazi-
las of Sunomganj District that were available on 
the days of our team’s visits gave 3 sputum sam-
ples, which were stained with ZN and examined 
 smear negative 
cases were ex-
cluded 
All smear-positive (ss+) cases were included 
Cultivation of all the cases at the Bangladesh TB 
National Reference Laboratory at Shyamoli 
Recultivation, DNA Fingerprinting and suscepti-
bility testing at  the Norwegian Institute of Public 
Health using RFLP 6110 and Spoligotyping. 
INCLUSION CRITERIA:  At least one positive 
culture. If more than one positive culture in the 
same patient, the first was included. If more than 
one clone in the same patient, one of each clone 
was included 
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2.2.2 Area and population at risk 
Sunamganj district of the Sylhet division of Bangladesh is a typical rural dis-
trict without any major urban areas located at the northeast border to India. According 
to the official statistics of the Bangladesh Bureau of Statistics for 1998 it had a rural 
population of 1.67 million and an urban population of 135 000. It consisted of 3670 
sqkm, and with its 552 citizens per sqkm it was less densely populated than the aver-
age 855 for Bangladesh. The crude birth rate was 18.60, compared to 19.87 for Ban-
gladesh. Especially the border areas used to be populated by a majority of indigenous 
people like Garo and Hajong, but recently there has been an immigration of Bengali 
speaking groups. The infrastructure is rather poor, and many villages are only acces-
sible by boat. It has been considered a remote and underdeveloped area within Ban-
gladesh [207]. According to the WHO, the 2003 annual risk of TB (ARTI) in Bangla-
desh was estimated to be 2,24%, which should give 40,364 new cases every year if 
Sunamganj is on the national average [208].  
 
2.2.3 Sample size 
The objective of the study was not only to test for drug resistance, but also to 
describe the epidemiology of the local M. tuberculosis population, and analyze the 
clustering patterns, with special emphasis on the spread of specific family strains. The 
project aimed to collect all strains isolated in the BRAC TB-clinics in the Sunamganj 
district for 1 year.  
Due to difficulties related to transport and decentralised treatment clinics, 
members of the research team could only be present a small proportion of the time at 
each clinic. And adding loss of cultures during transport and cultivation in Dhaka, we 
expected the total number for strains to arrive the NIPH in Norway to be 200.  
 
2.2.4 Collection of strains 
BRAC, the largest national NGO runs a TB Program in co-operation with the 
Government in all the Upazillas of the Sunamganj district. BRAC diagnose and give 
free treatment to a majority of the TB patients. Following the guidelines of the NTP, 
three sputum samples are collected from all attending patients. Short-course chemo-
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therapy (2HRZE/4H3R3) is given for pulmonary TB to sputum ss+ patients (infectious), 
under DOTS as close as possible to the community.  
The study intended to include all the ss+ cases detected by BRAC in Sunam-
ganj from November 2003 to December 2004, excluding the ss- and extra-pulmonary 
cases.  
 
2.2.5 Cultivation and susceptibility testing of the strains 
Four upazillas (sub-districts) in Sunamganj were included in the study. These 
were Chatak, Derai, Duarabazar and Sunamganj Sadar. The methods applied and the 
diversity of the M. tuberculosis  population included in this study has been presented 
previously [209]. The isolates were collected from November 2003 to December 2004 
(4 isolates were collected in early 2005). Due to the relative inaccessibility of the study 
area, sputa from 246 out of 743 ss+ cases diagnosed during the study period were 
refrigerated for approximately one week, during transport and prior to processing at 
the Centre for Health and Population Research (ICDDR,B). The samples were decon-
taminated following the standard procedure of Petroff [210], and inoculated on two 
Løwenstein-Jensen (L-J) slants for up to eight weeks. Out of the 246 sputa 148 iso-
lates of M. tuberculosis  were identified by the niacin accumulation- and nitrate reduc-
tion tests performed according to the WHO guidelines [211]. All mycobacterial isolates 
were transported to the National Reference Laboratory for Mycobacteria at NIPH in 
Norway, where they were re-cultivated and re-identified (Paper I). Identification was 
based on 16S-rRNA hybridization (AccuProbe; GenProbe Inc., San Diego, USA) or 
the niacin accumulation- and nitrate reduction tests [211]. Drug susceptibility testing 
(DST) was performed by the use of the Bactec MGIT 960 system (Becton Dickinson) 
following the standard user’s manual. The anti-TB drugs tested and the concentrations 
used were as follows: INH, 0.2 μg/ml; RMP, 2.0 μg/ml; EMB, 7.5 μg/ml; streptomycin, 
6.0 μg/ml. Multi drug resistance was defined as resistance to at least INH and RMP 
(Paper II). Cases previously treated for at least 1 month were defined as retreatment 
cases. 
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2.2.6 IS6110 RFLP and spoligotyping 
Fingerprinting with IS6110 RFLP was started by harvesting of DNA from a 
bacterial culture. Unlike for PCR-based methods like spoligotyping, a relatively large 
quantity of DNA is required [212]. Thereafter DNA was digested with the restriction 
enzyme PvuII and the restriction fragments were separated by electrophoresis on an 
0.8% agarose gel. The separated restriction fragments were transferred to a 
GeneScreene Pluss membrane (DuPont Boston, Mass.) by Southern Blotting. Hybridi-
sation in order to visualize the IS6110-containing restriction fragments was done with 
a 245-bp digoxin-labelled PCR-amplified probe with a DNA sequence complementary 
to the IS6110 DNA sequence.  
 
Spoligotyping 
Spoligotyping is based on the in vitro amplification of the DNA of the DR ge-
nomic locus present in the M. tuberculosis chromosome [57]. The reverse primer is 
biotinylated at the 5' end. A set of 43 oligonucleotides, each corresponding to one of 
the unique spacer DNA sequences within the DR locus, are covalently bound to a 
commercially available membrane. For hybridization, 20 
l of the PCR product is di-
luted and heat denatured. The samples are pipetted into parallel channels of a 
miniblotter in such a way that they are perpendicular to the rows of oligonucleotides. 
The hybridization is performed for 60 minutes at 60°C. The membranes are incubated 
with streptavidin-peroxidase conjugate for 60 minutes at 42°C. The patterns are visual-
ized by use of the chemiluminescence and by exposure of the membrane to an X-ray 
film. The results are analyzed manually and by computer assistance. 
Compared to other fingerprinting techniques spoligotyping requires less ex-
pensive equipment, so it can be utilized in laboratories with limited resources. It has 
also been demonstrated that the results are highly reproducible [213]. Tools like the 
SpolDB4 database [11] and the web-based computer algorithm 'Spotclust' searches 
[214] can be performed to assign isolates to specific families, subfamilies and variants. 
SpolDB4 is the largest and most up to date available global database for spoligotypes. 
Databases like SpolDB4 are important sources of knowledge of the world-wide spread 
of specific families of M. tuberculosis. 
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DNA isolation and IS6110 RFLP were performed as previously described by 
van Embden et al. [212]. The Bionumerics software (Applied Maths, Belgium) was 
used to calculate the genetic relationship between the patterns and generate the den-
drogram. The analyses were based on the Dice coefficient. A cluster was defined as 
two or more isolates from different patients with identical RFLP typing patterns. Spoli-
gotyping was performed as described elsewhere and according to the manufacturers 
instructions [213].  
Nieman et al. tested the stability of M. tuberculosis IS6110 fingerprint patterns 
and spoligotypes by analyzing serial isolates from patients with drug-resistant TB and 
found that the IS6110 fingerprint patterns of M. tuberculosis isolates have high de-
grees of stability. Compared to IS6110, the direct repeat (DR) region, which is the ba-
sis for spoligotyping, has a lower rate of change [215]. 
 
2.3 ETHIOPIA 
2.3.1 Study group and design 
In an attempt to operationalize the Dye model of the infectious pool [148], we 
systematically recorded treatment delay (TD) in a population of 18.1 million individuals 
in the Amhara Region of Ethiopia [216]. Each patient’s contribution to the infectious 
pool is equal to the number of days that he or she remains infectious, that is, the inter-
val between the day the patient can recall the onset of symptoms and the day the pa-
tient starts treatment. Retreatment cases remain infectious until they are cured or die.  
By recording the treatment delay for new TB cases, retreatment cases and 
failures, and by estimating the number of undiagnosed cases, the total number of in-
fectious days and hence an estimate of the infectious pool can be calculated. 
A cross-sectional study was conducted between September 1, 2003 and December 
31, 2003. The following zones were randomly selected from the eleven basically rural 
zones in Amhara as study sites: North and South Wollo, North Gonder, North Shewa, 
East Gojam and Bahir Dar. The study sites were all the five hospitals that are available 
in the selected zones. Besides this, we included 15 health care centers. We did not 
include any health stations because they do not have diagnostic facilities for TB. Par-
ticipants were consecutively included and interviewed immediately after diagnosis until 
the intended sample size was achieved. The data was collected by nurses and health 
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officers who had been trained for the purpose. New ss+ pulmonary TB patients aged 
15 or more years were included in the original study on TD [199], but all categories of 
pulmonary TB patients were interviewed, and the data for the other patient categories 
were retrieved for the purpose of this study at a later stage. Patient register card, TB 
registration books and laboratory registers were crosschecked to assure the data qual-
ity and the collection of data was closely monitored by the study supervisors. The 
sample size was calculated using the formula required for determination of sample 
size for estimating single proportions. By taking a previous study performed in Ethiopia 
on TD, which showed a 58% proportion of more than one month delay, a 95% CI and 
a margin error of 5% the sample size was calculated to 373, 384 patients were in-
cluded. A pretested structured questionnaire was used to collect information on socio-
demographics, the major presenting symptoms of pulmonary TB, the duration of the 
major presenting symptoms, and the date of the first healthcare visit. The major pul-
monary symptoms included on the questionnaire were presence of cough for more 
than 3 weeks, production of sputum, chest pain, and hemoptysis. Patient register 
cards, TB registration books, laboratory registries and electronic data were cross-
checked and validated to ensure the quality of data. The annual numbers for 2003 
were interpolated. SPSS version 11.0 was used for analysis.  
 
3.3 NORWAY 
3.3.1 Study group and design 
From March 2005 to January 2007, 155 TB-exposed health care workers 
were included from three major University Hospitals in Norway: Haukeland Univer-
sity Hospital (HUS), Ullevål University Hospital (UUS), and Akershus University 
Hospital (AHUS). For inclusion in the study, exposed persons had to be in close 
contact (stay in the same room) with a sputum-smear positive pulmonary TB pa-
tient in a non-protected manner for at least 1 hour. Subjects were then grouped 
according to the time of exposure: ‘Low exposure’ was defined as 1 to 8 cumula-
tive hours of close contact, while more than 8 cumulative hours of close contact 
was considered to be ‘high exposure’. 
A control group of 48 non-exposed individuals were recruited from the 
non-clinical staff at AHUS. Only individuals without any known prior exposure were 
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included in this group. The mean age of the control group was 41 years, with a fe-
male:male ratio of 33:15. The exposed group had a mean age of 39 years, with a 
female:male ratio of 133:22. Ten employees came from TB high-endemic countries. 
Both groups lived in the same geographical area and consisted of employees at 
Norwegian hospitals with middle incomes. The exposed group was followed up 
according to the national guidelines, including TST and chest X- ray independent 
of the T-SPOT.TB test result [159]. All participants answered a questionnaire con-
cerning BCG vaccination status, former TB, previous exposure, and residency in 
TB high-endemic countries. Previous studies have demonstrated that individuals 
infected with TB complete their cellular immune response within 8 weeks after ex-
posure [217]. Thus, both the T-SPOT.TB test and the TST were performed as 
close to 8 weeks after exposure as possible (mean, 11.5 weeks). The subjects had 
not been tested previously by an IFN- test, so their pre-exposure T-SPOT.TB sta-
tus was not known. The last documented TST found in the hospital records and 
TST results obtained 8 weeks after exposure were used as the basis for determin-
ing infection status. The study was approved by the Regional Committee for Medi-
cal Research Ethics East (REK Øst). Informed consent was obtained from all par-
ticipants, clarifying that follow up and treatment would be offered regardless of par-
ticipation and according to national guidelines [159]. 
 
 
Tuberculin skin test 
TSTs of both exposed personnel and controls were performed according to 
the Mantoux method with Purified Protein Derivate (PPD) RT 23 SSI, (2 TU) from 
Statens Serumsinstitut (SSI), Copenhagen, Denmark. Transverse induration in mm at 
the injection site was measured after 48-72 hours, and the results were interpreted 
according to the national guidelines [159]. Reading of test results was repeated if the 
induration was large, showed signs of adverse reactions, or was difficult to read.  
 
 
T-SPOT.TB test 
The T-SPOT.TB test, (Oxford Immunotec, UK), was used according to the 
manufacturer’s instructions. The blood was always drawn prior to the TST to avoid 
any possible interactions caused by rapid homing of specific T-lymphocytes to the 
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tuberculin injection site. Venous blood drawn into Cell Preparation Tube (CPT) 
vacutainers (Beckton Dickinson, Oxford UK) was sent by courier service to the 
Norwegian Institute of Public Health in Oslo, and analysed within 6 hours. In brief, 
peripheral blood mononuclear cells (PBMC) were isolated from blood following 
centrifugation, washed and counted. PBMCs at a concentration of 250,000 
cells/well in AIM V® cell culture medium (Invitrogen Corporation, Carlsbad, USA) 
were stimulated with ESAT-6 and CFP10 in 96-well plates pre-coated with anti-
IFN- capture antibodies, and incubated overnight at 37oC in 5% CO2.  Medium 
only and mitogen (Phytohemagglutinin) were used as negative and positive con-
trols, respectively. The next day the T-SPOT.TB assay was developed by adding 
an alkaline phosphatase-conjugated detection antibody and substrate. Coloured 
spots, representing individual INF--producing T cells, were counted manually us-
ing a microscope. The results were recorded based on the definition of positive 
and negative reactions given in the instructions from the manufacturer. All initial 
positive results were confirmed by analysis of a second blood sample before they 
were reported as positive.  
 
Data handling and statistical analysis 
All data were entered into a central Microsoft Access™ database, ap-
proved by the Norwegian Data Inspectorate, and statistical analysis was performed 
with the Graph Pad Prism 4™ software.  
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3. RESULTS 
Paper I 
A total of 780 patients were positive for M. tuberculosis by sputum-smear mi-
croscopy at the BRAC TB clinics in Sunamganj district (Chatak, Derai, Duarabazar 
and Sunamganj Sadhar upazillas) during the study period. Out of these, the research 
team managed to collect 267 sputum specimens which were sent to ICDDR’B in 
Dhaka.  M. tuberculosis was isolated from 111 (42%) of these samples. The positive 
cultures were isolated evenly throughout the year. Of the 111 isolates, 5 carried less 
than 5 copies of IS6110. A high degree of diversity was found in the collected bacterial 
population. A total of 105 genotypes were observed among the isolates. Also, contrary 
to that commonly observed in studies from urban areas of South East Asia, only three 
strains carried a IS6110 RFLP pattern and spoligotype pattern that was typical to 
those of the BL. The large genetic diversity found by IS6110 RFLP analyses sug-
gested that the majority of TB cases in this isolated, rural area, of a high incidence 
country, represented an established epidemic and was dominated by three main 
groups of M. tuberculosis. Each of the three main groups of M. tuberculosis isolates 
that were demonstrated in the current study represented a genetic diversity of more 
than 60%. This suggested that the isolates within these groups had evolved in parallel 
The distribution of M. tuberculosis families in 111 TB patients of the Sunamaganj 
District of Bangladesh analysed according to the SpolDB4 database.  
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and that each group represented an established epidemic.  
These findings were confirmed by the spoligotyping. At the time of publishing 
of article 1, the SpolDB4  was not available. Analyzing our data with the SpolDB4 38 
(34%) of the isolates were clustered into 8 shared types, whereas 74 strains (66%) 
were unique. The strains were clustered into 8 major clades: 8% percent (3 BL and 6 
CAS) of all strains belonged to the modern principal genetic group 1 (PGG 1), 5.0% (2 
Haarlem 1, 1 LAM 7 and 3 LAM 9) belonged to PGG 2 and 3% belonged to the “mis-
cellaneous” PGG 3. However, the major dominating clade was the “ancestral” East 
African-Indian (EAI) clade. The low diversiy among non-identical isolates suggested 
that this represented an established epidemic. Also, it appeared that this epidemic 
only to a minor degree was influenced by recently imported and recently disseminated 
strains. Of the total strain population 8 (7%) belonged to the EAI 2 clade, 14 (13%) to 
the EAI 4 clade, 41 (36%) to the EAI 5 clade and 29 (26%) belonged to the EAI6 BD1 
clade.  
 
Paper II 
From November 2003 to December 2004 a total of 268 ss+ samples were col-
lected. M. tuberculosis could be recovered from 148 of these samples. Both finger-
printing and even more so the DST suffered from substantial contamination of the 
strains on arrival from Bangladesh. Despite repeated decontamination procedures util-
izing sodium laurylsulphate [218], DST results were produced for only 95 out of the 
148 isolates. The MGIT 960 system was utilized. Total resistance among new cases to 
any drug was 31%. Among new cases resistance to SM was found in 17% of the iso-
lates, 23% were resistant to INH, 2% to RMP, 12% to EMB and 2% (2 cases) were 
MDR-TB. There were 11 previously treated cases. Among these, 3 were resistant to 
SM and 4 to INH. Total resistance to any drug, among all cases (new and previously 
treated cases) was 32%. A total of 18% of all cases were resistant to SM, 24% to INH, 
2% to RMP, 11% to EMB,  and 2% of all cases were MDR-TB.  
The highest rate of resistance was found for INH (24%), followed by SM 
(18%). Resistance to two or more drugs was seen in 10.5% of the cases, but the most 
unexpected finding was the relatively high resistance to EMB (12%).  
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Paper III 
Early diagnosis and immediate initiation of treatment are essential for an ef-
fective TB control program. Delay in diagnosis is significant to both disease prognosis 
at the individual level and transmission within the community. Most transmissions oc-
cur between the onset of cough and initiation of treatment. Paper III describes a sys-
tematic review of 58 studies addressing delay in diagnosis and treatment of TB. We 
found different definitions of, for example, debut of symptoms, first appropriate health 
care provider, time to diagnosis, and start of treatment. Rather than excluding studies 
that failed to meet strict scientific criteria, we tried to extract the "solid findings" from all 
of them to arrive on a more global understanding of diagnostic delay in TB.  
The main factors associated with diagnostic delay included human immu-
nodeficiency virus; coexistence of chronic cough and/or other lung diseases; negative 
sputum smear; extrapulmonary TB; rural residence; low access (geographical or 
sociopsychological barriers); initial visitation of a government low-level healthcare fa-
cility, private practitioner or traditional healer; old age; poverty; female sex; alcoholism 
and substance abuse; history of immigration; low educational level; low awareness of 
TB; incomprehensive beliefs; self-treatment; and stigma.  
The core problem in delay of diagnosis and treatment seemed to be a vicious 
cycle of repeated visits at the same healthcare level, resulting in nonspecific antibiotic 
treatment and failure to access specialized TB services. Once generation of a specific 
diagnosis was in reach, TB treatment was initiated within a reasonable period of time. 
 
Paper IV 
The median infectious period for retreatment cases, defined as the time from cease of 
primary treatment to start of new treatment, was 60 days. It was estimated that ap-
proximately 33% of all new ss+ PTB cases were undiagnosed or not notified by the 
NTP. The estimated infectious period of each undiagnosed case was 60 days, thus 
these cases contributed 150,360 days to the infectious pool. There were 75 retreat-
ment cases contributing 3,675 days to the infectious pool. There were also 60 treat-
ment failures, which because of their long infectious period of 365 days, made a sub-
stantial contribution of 21,900 days to the infectious pool. There were 5,013 new ss+ 
PTB cases, each with a median TD of 95 days. These cases made the largest contri-
bution to the infectious pool (476,235 days). The largest group of patients was the 
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6,159 ss- PTB cases who initiated TB treatment. Estimating their infectiousness as 
20% of that of the ss+ cases, they had an infectious period of 20 days and contributed 
123,180 days to the infectious pool. The total estimated infectious pool for the Amhara 
region in 2003 was 775,350 days, or 4,284/100 000 pop. 
 
Paper V 
Among the 155 exposed health care workers tested, 27 individuals were 
defined as new TST positive cases after recent exposure, while only 3 of these had 
a positive T-SPOT.TB test. There were no indeterminate test results, and no ex-
cluded HCW or T-SPOT results. The number of T-SPOT.TB positives represents 
11% of the individuals defined as new TST positives after exposure (3/27) and 2% 
of the total number of exposed people tested (3/155). In addition, 15 individuals 
had been previously defined as TST positive before exposure. Only 2 were T-
SPOT.TB positive: one was born in a TB high-endemic country, and the other had 
been previously treated for pulmonary TB. Interestingly, the former had a negative 
TST at the time of immigration to Norway, raising a question concerning the source 
and place of infection. 
All individuals detected as T-SPOT.TB positive belonged to the infected 
group, and percentage concordance between T-SPOT.TB and TST, including both 
previous and new TST positives, was 12% (5/42). Thus, the frequency of latent TB 
in the total cohort was 3% (5/155), whereas the TB transmission rate in the actual 
TB exposure study was estimated at 2 % (3/155). The 48 control participants were 
all T-SPOT.TB negative, but 3 persons in the control group were TST positive. 
The average time between first exposure and testing was 11.5 weeks. 
Among the exposed individuals, 51 participants belonged to the “high exposure” 
group (> 8 hours), and 104 participants fell into the “low exposure” group ( 8 
hours). There was no correlation between length of exposure and TST results. In 
addition, there was no correlation between T-SPOT.TB positivity and TST results. 
For the 3 T-SPOT.TB positive individuals infected after known exposure, two were 
exposed  8 hours and one was exposed > 8 hours. 
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4. DISCUSSION AND CONCLUSIONS 
4.1 MOLECULAR EPIDEMIOLOGY OF M. TUBERCULOSIS                 
IN BANGLADESH 
4.1.1 A high degree of diversity and predominance of the “ancestral” East 
African-Indian clade 
In the current study, a high degree of diversity among the M. tuberculosis 
population and low prevalence of the Beijing genotype was demonstrated in a rural 
area of Bangladesh (Paper I). The local M. tuberculosis population was dominated by 
the the EAI clade. These findings have also been confirmed by other studies in Ban-
gladesh where 44-56% of M. tuberculosis collections have been assigned to the EAI 
linage [4, 117, 219]. Most strains of the EAI clade could be classified into EAI1 to EAI5. 
Within the EAI clade, 49 strains of the current collection had the spoligotype signature 
designated EAI6-Bangladesh 1 (EAI6-BGD1). It thus appears that “ancestral” TB 
clades  like the EAI [40] are predominant in rural Bangladesh. This indicates that these 
strains have been present in the area for long periods and may thus have been en-
demic for many decades. The large diversity found by IS6110 RFLP analyses also 
suggested that the majority of TB cases included in our study represented an estab-
lished epidemic since it was dominated by three diverse groups of M. tuberculosis 
where most isolates had at least one other closely related strain.  The spread of TB in 
the Sunamganj district was not caused by any predominant individual strain, thus a 
significant contribution to the TB burden in this highly endemic country seems to be 
caused by endogenous reactivation. Although a large genetic diversity has also been 
demonstrated in a rural area of India [220], these findings are opposed to the findings 
of many urban-based South East Asian studies that have found that Beijing genotypes 
contribute to major outbreaks and transmission hot-spots of TB [134, 221]. 
 
4.1.2 Our study could indicate that the recent global dissemination of the 
Beijing genotype has not yet reached remote areas of Bangladesh 
From 2001 to 2003 Rahim et al. collected 224 M. tuberculosis strains from 
non-hospitalized patients from Dhaka and Matlab, a rural area 45 km southeast of 
Dhaka. The BL comprised 15% of the strains, both among the rural and urban patients 
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[117], compared to 32% BL found by Banu et al. among TB patients in a Dhaka hospi-
tal [4]. The higher BL proportion among the hospitalized TB patients could be due to 
the selection of resistant cases, but is else difficult to explain. The equal distribution of 
BL between Matlab and Dhaka in the study by Rahim et al. could indicate that a dis-
tance of 45km does not make a substantial difference. The split dotted beginning of 
the figure below depicts the difference of BL prevalence in Dhaka found by Banu et al. 
(32%) and Rahim et al. (15%). 
 
A study from Mymensingh, 120km North of Dhaka, found 7% BL strains [219], 
and our study from Sunamganj, which is 250km North of Dhaka, found 3% BL. It 
seems that the further away from Dhaka, the less spread of BL strains. Our findings 
indicated that the recent global dissemination of the Beijing genotype has not yet 
reached remote areas, such as Sunamganj of Bangladesh. If the Beijing genotype is 
heterogeneously spread throughout areas in high-incidence countries, it lends support 
to the hypothesis that this family represents a relatively new epidemic and that the Bei-
jing genotype may fuel a current change in the global M. tuberculosis population. 
Other possible contributing factors to the low presence of BL in isolated rural 
areas could be the absence of drug pressure (until recently), and the lag in shift to-
wards new strains caused by latency or that the BL requires higher CCS than other 
lineages. 
For the rural areas of Bangladesh a consequence of our knowledge of the 
epidemic situation must be to give first priority to prevent new emerging strains from 
urban hospitalized 
urban non-hospitalized 
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spreading. The previously described decentralized and community based BRAC 
model (1.9) with high case detection and treatment completion rates is an outstanding 
example of how this can be achieved. 
 
4.2 DRUG RESISTANCE IN THE SUNAMGANJ DISTRICT  
4.2.1 Presence of MDR-TB as expected - standard treatment regimen for 
TB still effective for the majority of the ss+ cases.  
The rate of MDR-TB (2%) was higher than that identified in rural areas of 
Mymensingh, both in 1995 and 2001 [222], but due to the limited number of isolates in 
our material the difference is not significant (Paper II). A low prevalence of RMP re-
sistance (1.1%) and MDR-TB (0.4%) for new cases was demonstrated in 1995 before 
DOTS was established in Bangladesh, and these levels dropped after the introduction 
of DOTS [182, 223]. The same success with DOTS has been observed in BRAC op-
erated rural areas like Sunamganj [224]. In Matlab, another rural area, also studied 
after the introduction of DOTS, MDR-TB was absent among new cases, while it was 
common (27.3%) among previously treated cases [184]. Studies from rural India 
(1997-2003) show that primary resistance to RMP is 0.5-4.4%  and that the preva-
lence of MDR-TB is 0.5-3% [185]. The same range of frequencies of MDR-TB among 
new cases are described in Myanmar (4.2%) [186], Thailand (4.2%) [187], and China 
(4.5%) [188]. The same levels of MDR-TB have also been described in the urban 
areas of Dhaka [184, 225, 226]. The frequency of MDR-TB found in Sunamganj was 
therefore not unexpected, since it corroborated to previous studies. Together, these 
studies indicate that the prevalence of MDR-TB is higher in urban areas of South East 
Asia than in rural areas. Also, MDR-TB is more common among retreatment cases 
than among new cases.  Our study indicated that the NTP of Bangladesh has adopted 
a standard treatment regimen for TB that is still effective for the majority of the ss+ 
cases. 
 
4.2.2 High rates of resistance to isoniazide, streptomycin and ethambutol  
The high rates of resistance to INH (24%) and SM (18%) presented in Paper 
II, most likely reflected that a majority of the current patients were infected many years 
 76 
ago, when the most prevalent drugs SM and INH were frequently used in mono-
therapy [180]. This should imply a low rate of recent transmission which is in accord-
ance with what was demonstrated by use of IS6110 restriction fragment length 
polymorphism (Paper I). Among the isolates within this population of M. tuberculosis 
most originated from patients found not to have been recently infected [209]. Since the 
most potent bactericidal effect of INH is in the early phase of treatment [227], re-
sistance to this drug is an important indicator of the emergence of drug resistant TB. 
An increased risk of treatment failure has also been demonstrated in areas with high 
levels of INH resistance. A high proportion of INH resistant strains may develop resis-
tance also to RMP [228, 229] and thus acquire MDR-TB. The high level of INH resis-
tance identified in the current study was therefore alarming and justifies follow up 
studies as well as a close monitoring of the DST levels among M. tuberculosis isolates 
of the Sunamganj area of Bangladesh. 
The relatively high rate of resistance to EMB (12%) found in the current study 
was similar to the substantial rate of resistance to EMB found in Matlab (14 %) [184]. 
In Mymensingh however, resistance to EMB was not found [182, 223]. We believe 
these discrepant results indicate that marked regional differences exist in EMB sus-
ceptibility among the various local M. tuberculosis populations in Bangladesh. It may 
however, also reflect the non-standardized techniques related to performing and inter-
preting sensitivity to EMB.   
In conclusion, our study demonstrated that DST is needed and possible in  
low infrastructure areas of developing countries like Sunamganj in Bangladesh. A 
prompt response to the world-wide increasing drug resistance must be to establish 
DST facilities. From an epidemiological point of view, to treat MDR-TB cases with first 
line drugs will rapidly deteriorate the situation. A major task must be to establish well-
organised transportation systems and quality-assured chains of DST facilities.  
 
4.3 LOGISTICS AND VALIDITY OF THE SUNAMGANJ STUDY 
The current studies raised some questions related to diagnosis, molecular 
fingerprinting and drug susceptibility testing of M. tuberculosis isolates from remote 
areas like Sunamganj. The field staff participating in the current study could only be 
available for sputum collection for 268 of the 743 ss+ TB cases diagnosed during the 
study period in these upazillas. The sputum samples that were collected could not be 
processed on the day of sampling. The current area is only accessible by small boats 
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during most parts of the year. Samples were kept in refrigerators, but between points 
and overnight during transport to ICDDR,B had to be stored in cooling boxes. Traore 
et al. found that the loss of mycobacteria was minimal in sputa stored at 2-40 C for up 
to 14 days. At 370 C however, they observed a complete destruction of mycobacteria 
present in the samples [230]. Despite attempts to maintain refrigeration all the way to 
Dhaka it cannot be ruled out that some strains were lost during this transport. It ap-
pears likely that the loss of M. tuberculosis cultures due to unavailability of field staff, 
local storage prior to shipment, and exposure to non-refrigerated temperatures was 
random. In such cases, it is unlikely that specific groups of M. tuberculosis with par-
ticular fingerprints or sensitivity patterns are favoured. We therefore believe that the 
isolates were representative of the TB epidemic of Sunamganj.  
 
4.4 REASONS FOR DIAGNOSTIC DELAY IN THE DIAGNOSIS AND 
TREATMENT OF TB 
4.4.1 Major findings 
Our analysis demonstrated that the interacting factors affecting patients’ 
health-seeking behavior and the availability of TB diagnosis and treatment can be 
categorized as involving either the patient or health care system. Most factors influ-
enced both patient and system delay, but some factors were more closely related to 
patient delay: alcohol or substance abuse, poverty, low access to health care facilities, 
rural residence, old age, belonging to an indigenous group and incomprehensive atti-
tudes, beliefs and knowledge about TB. Other factors were evidently more linked to 
health care delay: coexistence of chronic cough and/or other lung diseases, having 
extrapulmonary or negative sputum smear TB, less severe and indifferent symptoms 
or absence of haemoptysis, poor health care infrastructure and seeking traditional and 
private practitioners first. As patients continue to go untreated, absent isolation, both 
components equally contribute to the infectious pool.  
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Important factors related to patient delay 
 
alcohol or substance abuse 
poverty 
low access to health care facilities 
rural residence 
old age 
belonging to an indigenous group 
attitudes, beliefs and knowledge 
 
Important factors related to health care delay 
 
chronic cough  
other lung diseases 
negative sputum smear TB 
extrapulmonary TB 
less severe and indifferent symptoms  
absence of haemoptysis 
poor health care infrastructure 
seeking traditional and private practitioners first 
 
The vicious circle of repeated visits at the same level          
is the core problem of diagnostic delay 
 
4.4.2 Seeking a traditional practitioner first causes delay 
A range of studies have shown that selection of a traditional practitioner for 
the first visit is associated with a prolonged delay in diagnosis [231-240]. In Yimer et 
al.’s study from Ethiopia, patients who first visited a qualified medical provider experi-
enced a 21-day delay before initiation of treatment. Patients who first visited a tradi-
tional healthcare provider waited shorter (15 days) before first seeking healthcare, but 
the period from first visit to initiation of TB treatment was 4-fold greater than for the 
patients who visited a qualified medical provider first [199]. These findings are sup-
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ported by studies from The Gambia [238], Tanzania [231], and Penang (Malaysia) 
[241]. 
4.4.3 Poor access to the local NTP and stigma  
Many studies describe a bottleneck in reaching the local unit of the NTP. 
Multiple studies observed poor access to the NTP as one of the main factors in de-
layed diagnosis [15, 199, 231, 232, 235, 237, 239, 242-250]. In many high endemic 
countries, it appears crucial that a unit of the NTP is within a 1-day walking distance, 
as many patients have limited access to motorized vehicles. In addition to geographic 
distance, the studies identified several other barriers. One of the most important bar-
rier is stigma [232]. Many patients were highly reluctant to visit the NTP facility, be-
cause it would mean disclosing to the public that they had TB. Even worse, in many 
countries, TB is so closely linked to HIV that patients fear they are revealing their HIV 
status to their neighbours [240]. Also, many of the NTP personnel are unfriendly. Pa-
tients feel deprived of both privacy and dignity. The widespread introduction of DOTS 
also means that patients must visit daily so that their consumption of medication can 
be directly observed; this is perceived as humiliating, time consuming, and a threat of 
a substantial loss of income [199, 251, 252]. A marginal farmer or a day labourer will 
often have to choose between treatment and placing food on the table for his family. 
Most of the studies from developing countries demonstrated a significant link between 
delayed diagnosis and poverty.  
 
4.4.4 The non-specific nature of symptoms and self-treatment 
Most of the studies in our review also demonstrate the non-specific nature of 
symptoms and the disease’s first natural history as a core problem [201, 243, 245, 248, 
253, 254]. In The Gambia, TB is often misdiagnosed as malaria or viral infections [238].  
Several studies also highlight the problem of incorrect self-diagnosis including 
incorrect self-treatment [199, 233, 246]. In the study in Pakistan, more than 50% of 
patients practiced self-treatment, and 42% first searched a pharmacy for their symp-
toms [232]. Many studies link this to the problem of stigma, in fact the unhappy triad of 
incomprehensive beliefs, low awareness, and stigma.  
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4.4.5 The vicious circle of repeated visits at the same level is the core 
problem  
Our analysis revealed that the vicious circle of repeated visits at the same 
level is the core problem of diagnostic delay in most high endemic countries. TB is a 
rare disease, and more than 95% of patients with chronic cough seeking treatment at 
the level of primary healthcare do not have TB [153]. The delay in diagnosis on the 
part of health providers does not necessarily reflect inferior performance, but instead a 
lack of effective diagnostic tools and follow-up routines. Correct diagnosis requires 
both good training and available diagnostic facilities. The number of repetitions of this 
vicious cycle proved to be highly dependent on both the patient’s beliefs and aware-
ness of TB and the category of healthcare provider. In most countries, private practi-
tioners are consulted first, and this pattern is significantly associated with a longer di-
agnostic delay. This pattern is also recognized as a source of bottleneck in low en-
demic countries. A New Zealand study observed that the first consulting doctor often 
did not perform a chest X-ray, asked about previous TB, or obtained a sputum smear, 
although the patients had classical symptoms [255]. The same observations were 
made by Ward et al. in Australia [256]. Cough was treated symptomatically, and CXR 
were misdiagnosed.  
 
4.4.6 Why reduction in diagnostic delay should be a core target of all TB 
control programs 
Emphasis on the reduction of DD is not just an academic exercise; it is a cru-
cial task of all TB control programs. The nature of epidemics is that their reproductive 
rate has a dramatic impact on the epidemiological trend. Until the twentieth century, 
the reproductive rate for the TB epidemic was above 1.0 in Europe and North America 
[257, 258] . Small changes in the host-bacterium balance such as improved housing 
caused the TB epidemic to decline, long before specific treatment and preventive 
measures were available. In these same parts of the world, symptomatic sexually 
transmitted infections almost disappeared when effective antibiotics became available, 
with a sharp decline in the reproductive rate as the TD was reduced [259]. The same 
changes should occur with regard to TB, and the crucial task is to reduce the un-
necessary long treatment delay. A majority of the TB patients have been in touch with 
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the formal health services as early as two weeks after the start of the symptoms, but 
they are not identified. More than 95% of the patients who seek health care for chronic 
cough do not have TB [255]. How do we identify the 5% who have TB at the first con-
sultation, thereby preventing each from spreading TB? A crucial challenge is the lack 
of effective screening tests that are inexpensive and feasible at the primary health 
care level. If TD can be reduced and well organised specialized TB services are made 
available for all patients, the current rising world-wide epidemic may be reversed.  
 
4.5 THE UTILIZATION OF TREATMENT DELAY TO MONITOR THE IN-
FECTIOUS POOL OF TB IN A POPULATION 
As described previously, we theorized that a systematic recording of TD can 
be utilized as a feasible tool to monitor the size of the infectious pool at the local level. 
In our Ethiopian study we aimed at verifing this tool in a high endemic area. However, 
there are several demanding variables in our calculations, and substantial method-
ological challenges that need to be addressed.  
 
4.5.1 Size and nature of the undiagnosed group 
The WHO calculated the CDR for new smear positive cases in Ethiopia to be 
36% in 2003. As discussed in the background chapter, the CDR is built on old tubercu-
lin surveys extrapolated to the present situation [104]. For several reasons it is unlikely 
that there are 64% undiagnosed cases (WHO). First, pulmonary TB is generally a se-
rious disease with characteristic symptoms. The patient seeks treatment, self-cures, or 
dies within a few months [101]. In many communities, the traditional belief as well as 
the experience of previous generations is that if you get TB you will die [260]. After the 
introduction of modern medicines these beliefs seem to be changing.  Despite poverty 
and long distances to healthcare, most patients seek treatment, and they prefer 
allopathic medicine [261]. Our study on help-seeking behaviour in rural Bangladesh 
found that more than 90% of patients with symptoms of TB preferred to visit an allo-
pathic doctor first. Among the ten surveyed diseases, this was the one with the highest 
preference score for allopathic medicine [261].  
To estimate the size of the undiagnosed group a key question is: Are the non-
detected mostly not-ever detected, or are they not-yet detected? After DOTS is intro-
duced in a country, the number of new cases identified proceeds through distinct tran-
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sitional phases. This is illustrated by the development in The Sudan [260]. The na-
tional strategy was to first establish TB treatment facilities in the larger cities and main 
hospitals. This was followed by a steep rise in the number of diagnosed cases. After 
the introduction of the NTP at the district level, a further steady increase was expected, 
but this did not happen. Instead, after an initial small increase in the case finding, 
mainly involving women and children, a plateau was reached. The symptoms of TB 
were probably serious enough that patients travelled a long distance for care. Thus the 
main proportion of patients were diagnosed at a time when treatment facilities were 
only available in the main cities [260]. This indicates that most of the un-notified TB 
patients are not-yet detected rather than not-ever detected. They come forward and 
are notified sooner or later. 
Ethiopia is an important model to observe, because TB drugs are not avail-
able outside the NTP. Private practitioners as well as traditional practitioners all refer 
their TB patients to the NTP for treatment [199]. This makes Ethiopian data on the un-
diagnosed group more reliable than data from most other high endemic countries were 
TB drugs are sold on the open marked and a range of practitioners outside the NTP 
are providing treatment. A prevalence study was conducted by Shargie et al. in an 
area of Ethiopia with a well organized TB control program that had functioned in more 
than ten years [262]. To the authors' surprise they found that only one third of the total 
number of new ss++ where undiagnosed by the local TB control unit.  
This is further illustrated by an Ethiopian intervention study wherein 32 local 
communities were randomly allocated to a control group of passive case finding or an 
intervention group of active case finding through monthly diagnostic outreach clinics, 
house visits, and public gatherings. In the intervention area, case finding was not sig-
nificantly increased, but the TD was shortened. The proportion of patients with more 
than 3 months of symptoms was 41% in the intervention group and 63% in the control 
group. A sputum survey of 16,697 adults from the same area revealed a 2:1 ratio of 
ss+ cases receiving treatment to newly detected ss+ cases. The prevalence of ss+ TB 
was surprisingly low, only 78 per 100,000 [198, 262]. These studies were performed 
10 years after the introduction of an effective DOTS program with 75% coverage and a 
73% treatment success ratio [263].  
Given that the non-detected patients are mostly not-yet detected in the pro-
cess of reaching a diagnosis, 33% additional non-detected patients is in accordance 
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with the above mentioned studies, and we utilized this number as the base of our cal-
culations of the size of the undiagnosed group.  
In general, the relative number of un-notified cases, and the period they re-
main untreated differs between countries and the regions within them, and must be 
carefully estimated before calculating the infectious pool.  
 
4.5.2 Contribution of the sputum smear-negative cases  
Sputum- smear negative (ss-) PTB cases are generally less infectious, and 
their contribution to the infectious pool is not well studied. We based our calculations 
on two molecular studies: First a study in Greater Vancouver, Canada, which deter-
mined that ss- cases are responsible for at least one sixth of culture-positive episodes 
of TB transmission [264]. Secondly a study in San Francisco, California found that the 
source patient was ss- in at least 17% of the registered episodes of transmission, and 
it was estimated that ss- patients were 22% as likely as ss+ patients to transmit TB 
[46].  Studies like these, which demand an almost complete overview of the transmis-
sion in a population and the utilization of advanced molecular techniques, have not 
been performed in any high endemic country. However, we have no reason to believe 
that the infectiousness of ss- cases should be different from low to high endemic areas. 
Thus, in our estimate of the infectious pool ss- PTB cases contribute  to the infectious 
pool as 20% of the ss+ PTB cases, and we have divided the ss- PTB cases’ TD by 5 
to estimate their contribution to the infectious pool. 
 
4.5.3 Infectious period after start of treatment  
Two recent studies estimated the median time to sputum culture conversion 
after first-line treatment to 28 days [265] and 33 days [266], but the viability of the or-
ganisms rapidly deteriorate after treatment onset [267]. From several studies con-
ducted in the 1960s a practical conclusion was agreed that ss+ PTB patients remain 
infectious till on average two weeks after start of treatment [268, 269]. Taking into ac-
count the progressively reduced infectiousness, our estimate has added an infectious 
period of 15 days to each ss+ patient after the start of treatment. 
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4.5.4 Defining the onset and end of the infectious period 
Patient’s delay (PD) was defined as the interval between the onset of any 
symptom and the time at which the patient sought contact with any healthcare provider 
outside the household, including traditional practitioners. We chose to define the end 
of the delay as the day the patient started on treatment. Treatment delay (TD), which 
defines each patient’s contribution to the infectious pool, was thus defined as the in-
terval between debut of any symptom and the start of treatment.  We justify this ap-
proach based on the fact that the infectious period is the period during which the pa-
tient coughs, and according to multiple studies, coughing is the cardinal first symptom 
of approximately 95% of ss+ patients [199, 270]. Usually, the patient can accurately 
define the onset of their symptoms, and even distinguish a new coughing pattern from 
previous coughing patterns with other causes such as COPD or smoking [245]. The 
first symptom is important information and can be obtained with little extra effort by 
adding a question to patient registration forms. Moreover, this variable is not easily 
susceptible to “target perversion”, which means that it is not so easy to manipulate to 
fulfill official demands and goals; it is information provided directly by the patients and 
recorded in the NTP files.  
 
4.5.5 Conclusions 
We found that by addressing systematically the challenges of each variable in 
our calculations we obtained a realistic estimate of the infectious pool of TB in the 
population. Although there are still questions to be answered and more research to be 
done regarding the accuracy of the calculations, there is one application that is par-
ticularly usefull, especially at the local level; to monitor the trends. Still the validity of 
our approach needs to be confirmed. But, provided the recording is done systemati-
cally over time, changes in the infectious pool should be possible to obtain with high 
levels of accuracy, and be of substantial value, especially in monitoring epidemiologi-
cal trends and the performance of the local TB program. 
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4.6 USE OF INTERFERON GAMMA-BASED ASSAY TO DIAGNOSE 
TUBERCULOSIS INFECTION IN HEALTH CARE WORKERS AFTER 
SHORT EXPOSURE  
A positive TST has previously been considered the gold standard in screening 
for M. tuberculosis infection. However, there is currently no definitive way to decide 
whether a person is latently infected with M. tuberculosis. A recent prevalence study 
by Soborg et al. in a Danish hospital confirmed earlier findings that TST is hampered 
by low specificity in BCG-vaccinated individuals [271, 272]. The authors found a 34% 
prevalence among TST-positive HCWs, but the only significant risk factor associated 
with a positive TST was prior BCG immunisation; no association was observed with 
other important risk factors, such as occupational exposure to TB or hospital staff posi-
tion [271]. Other studies in low-endemic countries have also found that a positive TST 
test is primarily associated with prior BCG vaccination [273]. Nevertheless, how can 
we conclude that the low post-exposure rate of infection detected by T-SPOT.TB in 
our study represents the real situation if there is no gold standard? One possible strat-
egy is to estimate the likelihood of having latent TB infection by calculating a contact 
score that quantifies exposure to and infectiousness of the index case, as was done 
by Shams et al. [274]. A range of other studies also provide extensive evidence that 
the IGRAs correlate better to exposure than does TST. Therefore, we based our con-
clusions regarding the prevalence of TB infections on the T-SPOT.TB test [167, 273-
279]. 
Of 155 exposed HCWs and 48 healthy controls, all but one had a visible scar 
from BCG immunisation, which has been compulsory in Norway at the age of 14 until 
recently. Norwegian legislation also demands that all HCWs are asked for a certificate 
of TST at the time of appointment, and if the existence of a recent TST cannot be doc-
umented then a new TST is performed. The high correlation between BCG vaccination 
and a positive TST and the high specificity of the T-SPOT.TB test for M. tuberculosis 
infection (98%) make it likely that these are mostly false positive TST reactions rather 
than false negative T-SPOT.TB reactions. In addition, the boosting effect of repetitive 
skin testing in health personnel may also contribute to the somewhat surprisingly low 
concordance between infection status according to T-SPOT.TB and TST that was ob-
served in this study (12%). The accuracy of the T-SPOT.TB test is also supported by 
the fact that all five T-SPOT.TB-positive individuals also had a strong positive TST. 
Previous studies indicate that T-cell–based assays such as T-SPOT.TB and QFT are 
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more specific than TST, as they are not confounded by previous BCG vaccination or 
exposure to a large majority of other mycobacteria [167, 273, 279, 280]. Still, there is 
no diagnostic gold standard for latent TB and the fact that 89% of employees recently 
defined as infected by TST tested negative with the T-SPOT.TB test calls for further 
studies of kinetics and immune mechanisms in TB infection. 
In contrast to most other studies related to TB transmission within health insti-
tutions, we have in this work compared the performance of T-SPOT.TB and TST in a 
group of HCWs with well-defined short-term exposure to contagious TB patients in a 
hospital setting in a TB low-endemic area. In addition, the results have been used to 
evaluate the role of IFN- release assays in improving the surveillance of TB transmis-
sion to health personnel in a low-incidence country like Norway.  
Provided that the T-SPOT.TB results are the most reliable compared to TST 
results, our study indicates that the risk of infection among health care workers after 
short-term exposure to TB patients in a hospital setting is low (2%). This somewhat 
contradicts the findings of a Swiss long-term institutional study in which 15% of con-
tacts were T-SPOT.TB-positive after prolonged unprotected exposure [273]. Although 
both studies were performed in health care institutions in low incidence countries, the 
exposure time may account for the observed differences in transmission. A study from 
Denmark also reported a low proportion (1%) of latent TB among HCWs as detected 
by the QFT test [271]. However, these data were not based on recent exposure, but 
rather represent the general prevalence level among hospital personnel working in 
departments with TB patients. We found a prevalence level of 3% in our cohort. Not 
surprisingly, these results are in contrast to findings from a high-endemic country like 
Russia, where a study utilizing QFT revealed a prevalence level of 41% among hospi-
tal staff working with infectious diseases [136]. Several reports based on TST conver-
sion indicate that the risk of being infected may be high, even within a limited time 
frame of exposure [10, 281]. This has also been confirmed by a T-SPOT.TB study in 
Italy in which 32% of the staff in a maternity ward became positive for TB after a mean 
exposure time of 6 hours [280]. Compared to these findings, our study detected a low 
degree of transmission. However, it should be noted that the majority of the individuals 
in this study had been exposed for less than 8 hours before precautions were taken. 
Still, among the three persons with positive T-SPOT.TB tests (believed to be recently 
infected), two were exposed for less than 8 hours. The absence of a statistically sig-
nificant correlation between exposure time and both TST and T-SPOT.TB results is 
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probably due to both the low exposure time and the small number of participants, 
since these correlations have been demonstrated in many other studies [10, 280, 281]. 
Importantly, the results indicate that using IFN- release assays as an alterna-
tive to the present follow-up strategy based on TST results could save substantial re-
sources. Although TST by itself will be less expensive than a comprehensive labora-
tory procedure, the utilization of M. tuberculosis-specific blood tests has the potential 
to save major resources as the number of persons who must be followed up for 3 
years can be reduced by up to 89%. In this context, the possibility of avoiding un-
necessary and costly treatment, including serious side effects, is also of considerable 
importance. In addition, most exposed health care workers will avoid long-term anxiety 
by obtaining a negative result at an early investigational stage. Finally, the small num-
ber of infected persons who require treatment can be identified immediately. 
Oxlade et al. performed a 20-year cost-benefit analysis that used Markov 
modelling to compare the costs of TB screening with different strategies among hypo-
thetical cohorts of foreign-born immigrants to Canada and contacts of TB cases. 
Model inputs were derived from published literature and utilization of the QFT test. For 
entering immigrants, screening with Chest X-Ray would be the most cost-effective and 
QFT the least cost-effective strategy. Sequential screening with TST followed by QFT 
was more cost-effective than either QFT or TST alone. In contact tracing after expo-
sure, the most striking finding was that screening with TST followed by QFT, if positive, 
was more cost-effective than any other strategy. This was largely because TST alone 
was not effective if the exposed group had been vaccinated with BCG after infancy 
[282]. These findings were also confirmed in a Swiss study by Wrighton-Smith et al., 
estimating the costs of screening a cohort of 1000 individuals for latent tuberculosis; 
screening with TST alone followed by Chest X-Ray and clinical follow ups of the posi-
tive cases was estimated to 695820; T-spot.TB alone was estimated to 387135; 
TST followed by T-spot.TB of the positives was estimated to 342563, i.e. the less 
costly [283]. 
Due to the fact that BCG immunization has been administered routinely in 
Norway, specific blood tests should be introduced in all post-exposure contact tracing 
situations. Because TB transmission to health personnel in Norway seems to be rather 
low, the two-step screening approach (TST followed by IFN- release assay) might be 
attractive, and should be considered more closely from a cost-benefit perspective. It 
should also be noted that the QFT method, although less sensitive in immuno-
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suppressed individuals, has both logistic and economic advantages compared to the 
T-SPOT.TB assay, and implementation of the QFT has recently been suggested in 
Norway’s national guidelines. The introduction of specific T-cell based assays for post-
exposure screening and subsequent prophylactic treatment will become a rational and 
important component of the national TB control strategy. 
 
5. CONCLUSIONS 
We showed that a well established epidemic in rural Bangladesh represented 
a low rate of recent transmission. A majority of the strains belonged to the ancient 
East African- Indian (EAI) lineage (Paper I).  
Our study found that the total resistance among new cases to any drug was 
31%, 2% were MDR. The NTP in Sunamganj is still effective, although the high resist-
ance to INH is alarming (Paper II), and DST services were possible and highly needed. 
Due to the low rate of transmission in the high-incidence area, it was likely 
that most patients had been infected a long time ago. We thus wanted to measure the 
impact DD could have in similar high insidence settings (Paper IV). In order to study 
the impact of DD, an introductory review of published studies describing DD in numer-
ous countries was conducted (Paper III). We found the core problem in DD to be a 
vicious cycle of repeated visits at the same healthcare level, resulting in non-specific 
antibiotic treatment and failure to access specialized TB services.  
To reduce the DD there is an urgent need for alternative means to monitor the 
epidemic at the local level. We found that a systematic registration of treatment delay 
in the TB program records of the Amhara Region of Ethiopia could be utilized to esti-
mate the infectious pool of TB. By recording the treatment delay for new TB cases, 
retreatment cases and failures, and by estimating the number of undiagnosed cases, 
the total number of infectious days and, hence, an estimate of the infectious pool could 
be calculated (Paper IV).  
Since DD was considerable in the high-incidence setting we wanted to com-
pare to risk-groups in developed countries with a low-rate of TB (Paper V). Health care 
workers exposed to TB at three Norwegian hospitals as well as a non-exposed control 
group were tested with both TST and the INF- test T-SPOT.TB. Our data indicate that 
the frequency of latent TB in the total cohort of HCWs is 3% whereas the rate of 
transmission of TB to exposed individuals is around 2% and occurs through short time 
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exposure. Thus, the risk of TB transmission to health care workers following unpro-
tected TB exposure in a hospital setting in Norway is low.  
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Abstract
Background: Early diagnosis and immediate initiation of treatment are essential for an effective
tuberculosis (TB) control program. Delay in diagnosis is significant to both disease prognosis at the
individual level and transmission within the community. Most transmissions occur between the
onset of cough and initiation of treatment.
Methods: A systematic review of 58 studies addressing delay in diagnosis and treatment of TB was
performed. We found different definitions of, for example, debut of symptoms, first appropriate
health care provider, time to diagnosis, and start of treatment. Rather than excluding studies that
failed to meet strict scientific criteria (like in a meta-analysis), we tried to extract the "solid findings"
from all of them to arrive on a more global understanding of diagnostic delay in TB.
Results: The main factors associated with diagnostic delay included human immunodeficiency
virus; coexistence of chronic cough and/or other lung diseases; negative sputum smear;
extrapulmonary TB; rural residence; low access (geographical or sociopsychological barriers);
initial visitation of a government low-level healthcare facility, private practitioner, or traditional
healer; old age; poverty; female sex; alcoholism and substance abuse; history of immigration; low
educational level; low awareness of TB; incomprehensive beliefs; self-treatment; and stigma.
Conclusion: The core problem in delay of diagnosis and treatment seemed to be a vicious cycle
of repeated visits at the same healthcare level, resulting in nonspecific antibiotic treatment and
failure to access specialized TB services. Once generation of a specific diagnosis was in reach, TB
treatment was initiated within a reasonable period of time.
Background
Until the last part of the twentieth century, tuberculosis
(TB) was a major cause of death in both developed and
developing countries. Due to a range of factors such as the
human immunodeficiency virus (HIV) epidemic, popula-
tion growth, migration, socioeconomic changes, and
broad spread of aggressive and resistant new strains such
as the Beijing and W strains, a resurgence of TB has
occurred, even in low endemic areas [1]. In 1993, the
World Health Organization (WHO) declared a state of
global emergency for TB due to the steady worldwide
increase in the disease. Along with HIV and malaria, TB
has been declared a global enemy. In 2005, 12 million
new cases of tuberculosis were identified, a 58% increase
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from the 7.5 million estimated cases in 1990, and it was
estimated that in 2005 the disease caused 1.5 million
deaths worldwide [2].
The goal of TB control programs is to arrest transmission
within the community. Achieving this goal takes consider-
able time, because most individuals in endemic areas are
already infected, constituting a reservoir that continu-
ously contributes to the pool of infectious cases. An effec-
tive TB control program requires early diagnosis and
immediate initiation of treatment. Delay in diagnosis is
significant with regard to not only disease prognosis at the
individual level but also transmission within the commu-
nity and the reproductive rate of the TB epidemic [3,4].
Most transmissions occur between the appearance of
cough and initiation of treatment. Madebo et al found
that patients become more contagious as the delay
progresses; the longest delays are associated with the high-
est bacillary numbers on sputum smears [5]. Because TB
symptoms, particularly chronic cough with sputum, are so
prevalent in most societies, early contact with health serv-
ices causes delay rather than suspicion of TB. We found
that in Ethiopia patients with TB symptoms contact an
educated health worker on average after just 25% of the
total delay period [6]. Thus, there is a fourfold-difference
in the time of first contact and diagnosis.
Analysis of the factors leading to this delay between first
contact and diagnosis is crucial to combatting the increas-
ing TB epidemic. Although there are multiple studies of
delayed TB diagnosis, no one has performed a systematic
review.
Methods
Search strategy
We searched the following databases using the search
terms and strategy described in Table 1: the Cochrane
Infectious Diseases Group Specialized Register (February
2007); the Cochrane Central Register of Controlled Trials
(CENTRAL) published in The Cochrane Library (February
2007); MEDLINE (1966 to February 2007); EMBASE
(1974 to February 2007); and LILACS (1982 to February
2007). In addition, to identify unpublished and ongoing
studies, we contacted individual researchers in the TB field
as well as the WHO (2006) and the International Union
Against Tuberculosis and Lung Disease (IUATLD, 2006).
Selection and analysis
Only observational studies were selected. All obtainable
studies of patients receiving treatment for active pulmo-
nary TB that recorded at least the median or mean total
delay in diagnosis were included. The outcomes of inter-
est were diagnostic delay from the debut of symptoms to
the time of diagnosis or start of treatment. The titles and
abstracts of the identified reports were used to exclude
studies that clearly did not meet the inclusion criteria. For
studies deemed potentially eligible for inclusion, we
obtained the full paper. We screened the full articles of
selected studies to confirm eligibility and resolved any dis-
agreements by discussion. Our intent was not to exclude
studies based on strict scientific criteria, or to perform a
traditional quality assessment, but to make the studies as
comparable as possible.
We analyzed the studies with the intent of identifying dif-
ferences in approaches, rather than to define a gold stand-
ard. A primary aim was to describe the inevitable
inaccuracy that arises from the use of different definitions
of, for example, the debut of symptoms, first appropriate
health care provider, time of diagnosis, and start of treat-
ment.
Results
Search results
Our analysis revealed how complex it is to define diagnostic
delay, and there were major differences between studies
regarding inclusion and exclusion criteria, onset of symp-
toms, first contact and end of delay. First, the 58 studies
used different inclusion criteria. Seventeen studies included
all new TB cases, 11 included all pulmonary TB cases, 3
included all cases with a positive sputum smear, 24
included all new cases with a positive sputum spear, and for
3 studies data were not obtainable. Likewise, the study
exclusion criteria differed. Some studies carefully excluded
Table 1: Search terms and strategy
Search set CIDG SR CENTRAL MEDLINE EMBASE LILACS
1 Tuberculosis Tuberculosis Tuberculosis Tuberculosis Tuberculosis
2 Diagnostic delay Diagnostic delay Diagnostic delay Diagnostic delay Demora diagnostico*
3 Treatment delay Treatment delay Treatment delay
4 Treatment seeking Treatment seeking Treatment seeking
5 Case finding Case finding Case finding
6 Help seeking Help seeking Help seeking
CIDG SR: Cochrane Infectious Diseases Group Specialized Register
CENTRAL: Cochrane Central Register of Controlled Trials
*Demora diagnostico: Diagnostic delay
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all cases with chronic underlying pulmonary conditions
that could interfere with the patient's definition of symp-
tom onset, but most did not. Some studies excluded visi-
tors, mortal cases, and individuals with mental
disturbances. The age-related exclusion criteria also varied:
most studies excluded cases below the age of 16 years, some
excluded cases below the age of 18 years, and a few included
children of all ages. One study did not include patients who
had undergone 2 or more months of treatment.
Definition of the onset of symptoms was also variable.
Forty-nine studies defined onset as the debut of any symp-
tom, 2 studies defined onset as debut of cough, and 1
study defined onset as debut of any pulmonary symptom.
For 6 studies, a definition of symptom onset could not be
obtained.
With regard to definition of the first contact, 34 studies
defined the first contact as the first visit to a qualified
healthcare provider. However, some of these studies
included any allopathic ("western medicine") provider
within the category of a qualified healthcare provider; oth-
ers used the time of first contact with the national TB pro-
gram in defining the end of patient delay. Eighteen studies
defined the first contact as the time when the patient
sought contact with any healthcare provider outside the
household, including traditional practitioners. Four stud-
ies recorded both. Six studies did not provide any infor-
mation with regard to definition of the first contact.
The studies also applied different definitions of the end of
the delay. Seventeen studies defined the end of healthcare
system delay as the time when a correct diagnosis was
made (diagnostic delay), 20 studies defined it as the time
the patient started treatment (treatment delay), and 14
studies distinctly recorded both. Data of this kind were
unavailable for 7 studies.
Most studies defined the delay as a specific number of
days, but several studies defined it as greater than a spe-
cific period of time (e.g. >60 days, > 90 days), or delay was
defined as significantly longer in one group versus
another group. A cut off point of 30 days to dichotomize
into either delay on non delay was also commonly used.
Diagnostic delay
Table 2 lists the included studies in descending order
according to the total diagnostic delay. Not surprisingly,
the longest total delays (> 120 days) were reported for
some high endemic countries, with the exception of the
median 126-day delay reported by Lewis et al for East Lon-
don [7]. Most of the studies, whether investigating low or
high endemic countries, reported a total diagnostic delay
within the range of 60–90 days (mean ± standard devia-
tion: 72 days ± 28 days).
There was no consistent pattern with regard to the relative
contributions of patients and healthcare providers to the
diagnostic delay. The main delay was patient related in the
studies in London (Lewis et al), Romania, Vietnam,
Nigeria, South Africa, Australia (Queensland), Ethiopia
(Addis Abeba), Korea, Somalia, Syria, Turkey (Istanbul,
Okur et al), Japan (Chiba), Iraq, USA (New York), Yemen,
and China (Shanghai). The main cause of delay was iden-
tified as the healthcare system in the studies of Tanzania,
Ghana, Pakistan, Malaysia, Iran (WHO, nationwide), Bot-
swana, New Zealand, Uganda, Ethiopia (Amhara), Italy,
and China (Jianhu). Twelve studies reported a nearly
equal contribution of patients and healthcare system to
the diagnostic delay. The remaining studies did not record
the relative importance of these two factors in the diag-
nostic delay.
Symptoms prior to diagnosis
Twenty-five studies recorded the frequency of symptoms
reported by patients before diagnosis. The average fre-
quencies of the following five cardinal symptoms were
(number of studies listing the symptom in brackets):
cough 85% (25), fever 65% (24), weight loss 62% (22),
chest symptoms 50% (24), and haemoptysis 25% (22).
Other symptoms less frequently reported: sputum 67%
(5), fatigue 55% (8), and increased sweating 35% (10).
All but two studies defined the onset of patient delay from
the debut of any symptom [8,9], where the debut of cough
defined the start.
Risk factors for prolonged diagnostic delay
The possible risk factors for diagnostic delay were hetero-
geneous (Table 3). The study conclusions were also heter-
ogeneous; a risk factor for increased delay in some studies
was a risk factor for decreased delay in other studies. Some
factors were identified in numerous studies, while others
were mentioned by only one study or a few studies. Fol-
lowing is a brief analysis of the factors, which are further
elaborated in the "Discussion".
Clinical characteristics
The WHO study in Syria found HIV to be a risk factor for
increased delay in diagnosis [10], while three other stud-
ies concluded the opposite [11-13]. Four studies found
coexistence of chronic cough and/or other lung diseases
be a risk factor for increased delay [12,14-16]; one study
found the opposite [7]. Only a few studies included
extrapulmonary TB, and as expected three found that
patients with extrapulmonary TB experience longer delays
than do patients with pulmonary TB [7,17,18]. Three
studies found a negative sputum smear to be a risk factor
for increased delay [12,19,20]; one study found the oppo-
site (the WHO study in Egypt [15]). Six studies found
alcoholism or substance abuse to be a risk factor for
increased diagnostic delay [8,21-25]. Other health-related
BMC Public Health 2008, 8:15 http://www.biomedcentral.com/1471-2458/8/15
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Table 2: Median diagnostic delay for pulmonary TB patients in 58 studies
Country Year First author DD Pat DD HCP DD total Ref no.
Tanzania 2000 Wandwalo 15 120 136 [29]
United Kingdom 2003 Lewis 63 35 126 [7]
Burkina Faso 2006 Ouedraogo * * 120 [49]
Ethiopia 1999 Madebo * * 120 [5]
Ghana 1998 Lawn 28 56 120 [11]
Malawi 1988 Nkhoma * * 120 [54]
Thailand 1991 Tesana * * 120 [55]
Thailand 1993 Pungrassami * * 120 [45]
Romania 1989 Anastasatu 69 34 107 [33]
Iran 2002 Masjedi 13 93 [51]
Vietnam 1999 Long 54 29 93 [30]
Pakistan 2006 WHO 9 87 91 [27]
Malaysia 1994 Hooi 15 35 90 [21]
United States 2005 Golub 32 26 89 [22]
Iran 2006 WHO 24 42 88 [27]
Malaysia 1997 Liam 14 49 88 [36]
Botswana 1998 Steen 21 35 84 [26]
New Zealand 2000 Calder 7 49 84 [44]
Uganda 2005 Kiwuwa 14 63 84 [23]
Spain 2003 Altet Gomez 43 39 82 [24]
Ethiopia 2005 Yimer 15 61 80 [6]
Nepal 2001 Yamasaki-Nakagawa 23 29 79 [14]
Japan 1990 Niijima * * 78† [46]
Mongolia 1996 Enkhbat 29 35 78 [35]
Nigeria 2004 Odusanya 56 7 70 [19]
South Africa 2001 Pronyk 28 7 70 [8]
Australia 2001 Ward 30 11 66 [20]
Thailand 2006 Rojpibulstit 31 20 66 [9]
China 2004 Bai 30 24 65 [28]
Italy 2006 Gagliotti 7 36 65 [38]
Spain 1996 Franco 23 32 64 [12]
Turkey 2004 Güneylioglu 18 13 64 [16]
Ethiopia 2002 Demissie 60 6 64 [18]
Norway 2006 Farah 28 33 63 [17]
United States 1998 Asch 60s [42]
India 2002 Rajeswari 20 23 60 [25]
Korea 1992 Mori 54 14 60 [31]
Peru 1996 Chavez * * 60 [53]
The Gambia 2001 Lienhardt * * 60 [32]
Zambia 2001 Needham * * 60 [10]
Cambodia 2006 Saly * 10 58 [50]
Somalia 2006 WHO 53 7 58 [27]
Malawi 2000 Salaniponi * * 56 [47]
Syria 2006 WHO 31 15 55 [27]
China 2005 Xu 10 39 50 [37]
Turkey 2006 Okur 30 19 49 [34]
United Kingdom 2007 Rodger * * 49 [40]
Australia 1996 Pirkis * * 44 [15]
Taiwan 2005 Chiang 7 23 44 [56]
Egypt 2004 WHO 12 18 42 [27]
Japan 2002 Sasaki 21 7 42 [52]
Iraq 2004 WHO 31 2 36 [27]
United States 1999 Sherman 21 6 35 [39]
Yemen 2004 WHO 28 4 35 [27]
China 2006 Deng 19 5 31 [41]
France 1996 Gulbaran 30 [48]
Thailand 2001 Ngamvithayapong 11 8 * [13]
Pakistan 2001 Sadiq 21€ [57]
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risk factors identified include generally poor health [26],
smoking [14,23], coexistence of sexually transmitted dis-
eases [26], less severe and indifferent symptoms [27], and
absence of hemoptysis [16,28].
Socioeconomic factors
A range of studies found rural residence to be a risk factor
for prolonged delay [5,11,14,16,23,25,29-32]. This risk
factor seems to be closely linked to low access to health-
care and choice of settings in which to first seek healthcare
The studies are listed in descending order of the median diagnostic delay.
DD Pat (Diagnostic Delay by the Patients): Time from debut of symptoms to first visit to health care provider
DD HCP (Diagnostic Delay by the Health Care Providers): Time from first visit to a HCP to the making of a proper diagnosis
DD Total (Total Diagnostic Delay): Time from debut of symptoms to the making of a proper diagnosis
* Data not obtainable
† Average calculated by the reviewers from separate numbers for female and male
 Mean
s 80% percentile
€ 77% percentile
Table 2: Median diagnostic delay for pulmonary TB patients in 58 studies (Continued)
Table 3: Risk factors for diagnostic delay
Risk factor Positive association with risk Negative association with risk
HIV [10] [11-13]
Coexistence of chronic cough and/or other 
lung diseases
[12, 14-16] [7]
Negative sputum smear [12, 19, 20] [15]
Extrapulmonary TB [7, 17, 18]
Rural residence [5, 11, 14, 16, 23, 25, 29-32]
Low access to healthcare (geographical or 
socio-psychological barriers)
[6, 8, 10, 14, 18, 23, 25, 27-30, 34, 42, 47, 48, 
50]
Initial visit to government low-level healthcare 
facility
[5, 6, 9-11, 23, 26, 32-34] [35]
Initial visit to traditional or unqualified 
practitioner
[9, 10, 14, 26-29, 32, 36, 37]
Initial visit to private practitioner [9, 10, 14, 26-29, 32, 36, 37]
Initial visit to tertiary-level services/hospital [11] [13, 23, 38, 39]
Old age [5, 12, 14-16, 19, 23, 24, 26, 38, 40, 41] [18, 35]
Poverty [7, 20, 21, 27, 28, 34, 37, 40, 41, 47, 48, 54, 56] [18]
Female sex [8, 10, 11, 14-16, 20, 22, 31, 33, 39, 40] [5, 21, 23, 25]
Alcoholism or substance abuse [8, 21-25]
History of immigration [8, 15, 17, 22, 38, 39, 42]
Low educational level and/or low awareness 
and knowledge about TB
[9, 15-17, 20, 21, 23, 24, 27, 28, 31-33, 38, 39] [13] (low educational level)
Other Health-related reasons:
Generally poor health [26]
Smoking [14, 23]
Coexistence of sexually transmitted diseases [26]
Less severe and indifferent symptoms [27]
No haemoptysis [16, 28]
Socioeconomic factors:
Married [5]
Single [18, 26]
Large family size [30]
Farmer [5]
White (vs. aboriginal) [20]
Muslim [18]
Belonging to an indigenous group [13]
No insurance [13]
Beliefs and attitudes:
Beliefs about TB (not curable, caused by evil spirits, etc.) [8, 14, 27]
Stigma [27]
Self-treatment [6, 36, 42]
The columns are identifying the applicable studies finding positive and negative association, respectively, with the risk factors
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(see next section). Even among developing countries,
access to healthcare varied. For example, in Ethiopia the
public health service coverage was reported to be 50% [6],
whereas in The Gambia 87% of the population was
reported to have good access to healthcare [7,19,20,32].
The studies provided broad evidence that low access leads
to prolonged delay in diagnosis [5,7,9,13,17,20,27-33].
Sociopsychological factors
Seeking government low-level health care facility first
[5,6,9-11,23,26,32-34] (one study from Spain found the
opposite [35]). Initially seeking a traditional or unquali-
fied practitioner [9,10,14,26-29,32,36,37]. First seeking a
private practitioner was a clear risk factor for diagnostic
delay, independent of rural or urban residence [9-
11,14,15,19,21,23,24,26,28,35]. Four studies concluded
that seeking specialized services leads to a decreased diag-
nostic delay [13,23,38,39], while one study from the USA
[11] found the opposite.
Sociodemographic factors
A range of studies found old age to be a risk factor for
increased diagnostic delay [6,13,15-17,20,23,25,32,37-
39], while two studies found the opposite [18,35]. Also, a
number of studies concluded that females experience
increased diagnostic delay [8,10,11,14-
16,20,27,28,30,40,41]. However, a substantial number of
studies made the opposite conclusion [5,21,23,25]. In
addition, history of immigration or illegal residency
seemed to be a risk factor in countries where this is actual
[8,15,17,22,38,39,42].
Socioeconomic factors
Thirteen studies found low income and poverty to be a
risk factor for diagnostic delay
[3,7,17,23,24,31,34,38,39,43-46]. In a range of studies,
low educational level and/or low awareness and knowl-
edge about TB was listed as a risk factor for diagnostic
delay [5,10,16-18,21,23,25,27-29,34,37,47,48]. Only
one, from France [13], determined the opposite, finding
that low educational level was linked to immigration and
socially deprived groups where the health authorities
focused on TB.
Other socioeconomic risk factors identified by 1–3 studies
included being married [5], being single [18,26], large
family size [30], being a farmer [5], being white (vs. abo-
riginal) [20], being a Muslim [18], belonging to an indig-
enous group [13], and not having insurance [13].
Beliefs and attitudes
Beliefs about TB (TB is incurable, caused by evil spirits,
etc.) [8,14,27], stigma [27], and self-treatment [6,36,42]
were identified as risk factors in 1–3 studies.
The vicious circle of repeated visits at the same level
A majority of the studies identified as the direct or under-
lying problem a vicious circle of repeated consultations
with a multitude of healthcare providers without a correct
diagnosis. Several papers list multiple visits at the same
level, while others focus on multiple visits to the same
physician. Three groups of healthcare providers were par-
ticularly identified as sources of this vicious circle: pri-
mary-level government health posts, who have limited
diagnostic facilities and poorly trained personnel [5,6,9-
11,23,26,32-34]; private practitioners with low awareness
of TB [9-11,14,15,19,21,23,25,26,29,32]; and unquali-
fied vendors, quacks, and traditional practitioners
[9,10,14,26-29,32,36,37] In Burkina Faso for a patient
seeking a health post or a private practitioner, the progres-
sion towards specialized services was poor; patients had
repeated consultations at the same level, such that more
than 94% of patients underwent repeated courses of non-
specific antibiotics [49]. In Ghana, the health personnel
at government health posts have poor training in diagnos-
ing TB, and the specialized services of the NTP are over-
centralized [11]. In a study in Malaysia, only 11% of
patients received their diagnosis after the first consulta-
tion, and 45% received their first diagnosis after the third
consultation [21]. Another study from Malaysia similarly
indicates low awareness of the private practitioner as a key
problem [36].
Discussion
The studies had different definitions of a range of varia-
bles, for example, debut of symptoms, first appropriate
health care provider, time to diagnosis, and start of treat-
ment, and they were not directly comparable or suited for
a meta-analysis. Rather than excluding studies that failed
to meet strict scientific criteria (like in a meta-analysis), we
tried to extract the "solid findings" from all of them to
arrive on a more global understanding of diagnostic delay
in TB. Our detailed analysis demonstrates that the inter-
acting factors affecting patients' health-seeking behavior
and the availability of TB treatment can be categorized as
involving either the patient or healthcare. Most factors
influence both patient and health care delay, but some
factors were more closely related to patient delay: alcohol
or substance abuse, poverty, low access to health care
facilities, rural residence, old age, belonging to an indige-
nous group and incomprehensive attitudes, beliefs and
knowledge about TB. Other factors were evidently more
linked to health care delay: coexistence of chronic cough
and/or other lung diseases, having extrapulmonary or
negative sputum smear TB, less severe and indifferent
symptoms or absence of haemoptysis, poor health care
infrastructure and seeking traditional and private practi-
tioners first. As patients continue to go untreated, absent
isolation, both components equally contribute to the
infectious pool.
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Our analysis revealed that the vicious circle of repeated
visits at the same level is the core problem of diagnostic
delay in most high endemic countries. TB is a rare disease,
and more than 95% of patients with chronic cough seek-
ing treatment at the level of primary healthcare do not
have TB [43]. The delay in diagnosis on the part of health
providers does not necessarily reflect inferior perform-
ance, but instead a lack of effective diagnostic tools and
follow-up routines. Correct diagnosis requires both good
training and available diagnostic facilities. The number of
repetitions of this vicious cycle proved to be highly
dependent on both the patient's beliefs and awareness of
TB and the category of healthcare provider. In most coun-
tries, private practitioners are consulted first, and this pat-
tern is significantly associated with a longer diagnostic
delay. This pattern is also recognized as a source of bottle-
neck in low endemic countries. A New Zealand study
observed that the first consulting doctor often did not per-
form an X-ray, ask about previous TB, or obtain a sputum
smear – although the patients had classical symptoms
[44]. The same observations were make by Ward et al in
Australia [20]. Cough was treated symptomatically, and
CXR were misdiagnosed.
A range of studies have shown that selection of a tradi-
tional practitioner for the first visit is associated with a
prolonged delay in diagnosis [9,10,14,26-29,32,36,37].
In Yimer et al's study from Ethiopia, patients who first vis-
ited a qualified medical provider experienced a 21-day
delay before initiation of treatment. Patients who first vis-
ited a traditional healthcare provider waited 15 days
before first seeking healthcare, but the period from first
visit to initiation of TB treatment was 4-fold greater [6].
These findings are supported by studies of The Gambia
[32], Tanzania [29], and Penang [21].
Many studies describe a bottleneck in reaching the local
unit of the NTP. Multiple studies observed poor access to
the NTP as one of the main factors in delayed diagnosis
[6,8,10,14,18,23,25,27-30,34,42,47,48,50]. In many
high endemic countries, it appears crucial that a unit of
the NTP is within a 1-day walking distance, as many
patients have limited access to motorized vehicles. In
addition to geographic distance, the studies identified sev-
eral other barriers. One of the most important barriers is
stigma [27]. Many patients were highly reluctant to visit
the NTP facility, because it would mean disclosing to the
public that they had TB. Even worse, in many countries,
TB is so closely linked to HIV that patients fear they are
revealing HIV status to their neighbors [37]. Also, many of
the NTP personnel are unfriendly. Many patients feel
deprived of both privacy and dignity. The widespread
introduction of DOTS also means that patients must visit
daily so that their consumption of medication can be
directly observed; this is perceived as humiliating, time
consuming, and a threat of a substantial loss of income
[6,51,52]. A marginal farmer or a day laborer will often
have to choose between treatment and placing food on
the table for his family. Most of the studies from develop-
ing countries demonstrated a significant link between
delayed diagnosis and poverty
[7,20,21,27,28,34,37,40,47,48].
Most of the studies in our review also demonstrate the
nonspecific nature of symptoms and the disease's first nat-
ural history as a core problem [15,18,23,31,50,53]. In the
Gambia, TB is often misdiagnosed as malaria or viral
infections [32].
Several studies also highlight the problem of self-treat-
ment [6,36,42]. In the study in Pakistan, more than 50%
of patients practiced self-treatment, and 42% first
searched a pharmacy for their symptoms[27]. Many stud-
ies link this to the problem of stigma, in fact the unhappy
triad of incomprehensive beliefs, low awareness, and
stigma.
Conclusion
Our analysis is consistent with the findings of the WHO
Eastern Mediterranean Region study. They concluded:
"The private sector was the first choice for more than two-
thirds of the patients. The main determinants of delay
were: socio-demographic; economic; stigma; time to
reach the health facility; seeking care from non-special-
ized individuals; and visiting more than one health care
provider before diagnosis [3]." The core problem in delay
of diagnosis and treatment seemed to be a vicious cycle of
repeated visits at the same healthcare level, resulting in
nonspecific antibiotic treatment and failure to access spe-
cialized TB services. Once generation of a specific diagno-
sis was in reach, TB treatment was initiated within a
reasonable period of time.
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